var title_f25_7_25712="Abnormal lateral elbow";
var content_f25_7_25712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal lateral elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiograph of the elbow of a 2-year-old girl. Both the anterior and posterior fat pads are elevated (small arrows). In addition, the anterior humeral line passes along the anterior edge of the capitellum rather than through its center. Mild buckling of the posterior cortex of the distal humerus can be seen (large arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25712=[""].join("\n");
var outline_f25_7_25712=null;
var title_f25_7_25713="Plantar anatomy PI";
var content_f25_7_25713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Plantar fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plantar fascia is a tough band of tissue that connects the heel bone to the toes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25713=[""].join("\n");
var outline_f25_7_25713=null;
var title_f25_7_25714="Cutaneous lichen amyloid close-up";
var content_f25_7_25714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen amyloidosis in a patient with MEN2: Close-up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Cornelis J Lips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25714=[""].join("\n");
var outline_f25_7_25714=null;
var title_f25_7_25715="Benzalkonium chloride and benzocaine (topical): Patient drug information";
var content_f25_7_25715=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzalkonium chloride and benzocaine (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/5/26706?source=see_link\">",
"     see \"Benzalkonium chloride and benzocaine (topical): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15826921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viroxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15827279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15827278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4072023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzalkonium, benzocaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15827283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15827289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15827284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15827281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4072062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drink fruit juices or soft drinks (pop) for 1 hour after using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4072065",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not brush teeth for 1 hour after using.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15827282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15827285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat or open flame.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15827286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87455 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25715=[""].join("\n");
var outline_f25_7_25715=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826921\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827279\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827278\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827283\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827289\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827284\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827281\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827282\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827285\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827286\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/5/26706?source=related_link\">",
"      Benzalkonium chloride and benzocaine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_7_25716="Apical 5 chamber echo with color Doppler AR";
var content_f25_7_25716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/70063/5chcdarm_conv.mp4?title=Apical+5+chamber+echo+with+color+Doppler+AR\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical five chamber echocardiogram with color Doppler demonstrating aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Five chamber view from a 2-D echocardiogram shows a moderate amount of aortic regurgitation and left ventricular enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25716=[""].join("\n");
var outline_f25_7_25716=null;
var title_f25_7_25717="Intervillous thrombus";
var content_f25_7_25717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intervillous thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25717=[""].join("\n");
var outline_f25_7_25717=null;
var title_f25_7_25718="Typhoid vaccine: Drug information";
var content_f25_7_25718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Typhoid vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/59/10161?source=see_link\">",
"    see \"Typhoid vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/34/25125?source=see_link\">",
"    see \"Typhoid vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5275259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Typherix&reg;;",
"     </li>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Live (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"     One capsule on alternate days (day 1, 3, 5, and 7) for a total of 4 doses; all doses should be complete at least 1 week prior to potential exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Booster immunization (with repeated or continued exposure to typhoid fever):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: Repeat full course of primary immunization every 5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling: Repeat full course of primary immunization every 7 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     0.5 mL given at least 2 weeks prior to expected exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Reimmunization:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Typhim Vi&reg;: 0.5 mL; optimal schedule has not been established; a single dose every 2 years is currently recommended for repeated or continued exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Typherix&reg; (Canadian labeling; not available in U.S.): 0.5 mL every 3 years",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F232374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/34/25125?source=see_link\">",
"      see \"Typhoid vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years: Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years: I.M.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, enteric coated [live]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivotif&reg;: Viable",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty21a 2-6.8 x 10",
"     <sup>",
"      9",
"     </sup>",
"     colony-forming units and nonviable",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty21a 5-50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     bacterial cells [contains lactose 100-180 mg/capsule and sucrose 26-130 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [inactivated]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Typhim Vi&reg;: Purified Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL, 10 mL) [derived from",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty2 strain]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Typherix&reg;: Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL)  [derived from",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty2 strain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Typhim Vi&reg; and Typherix&reg; may be given I.M. and are indicated for children &ge;2 years of age; administer as a single 0.5 mL (25 mcg) injection in deltoid muscle.",
"     <b>",
"      Do not administer Typhim Vi&reg; or Typherix&reg; intravascularly.",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Swallow capsule whole soon after placing into mouth; do not chew or open capsule. Capsule should be taken with a cold or lukewarm beverage (&le;37C/98.6F). Take 1 hour prior to a meal. Avoid alcohol 1 hour before or 2 hours after administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure  patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization against typhoid fever caused by",
"     <i>",
"      Salmonella typhi",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not for routine vaccination. In the United States and Canada, use should be limited to:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &minus; Travelers to areas with a prolonged risk of exposure to",
"     <i>",
"      S. typhi",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &minus; Persons with intimate exposure to a",
"     <i>",
"      S. typhi",
"     </i>",
"     carrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &minus; Laboratory technicians with exposure to",
"     <i>",
"      S. typhi",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &minus; Travelers with achlorhydria or hypochlorhydria (Canadian recommendation)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      In the U.S., all serious adverse reactions must be reported to the Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection (incidence may vary based on age and/or product used):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Fever (undefined; 2% to 32%), malaise (4% to 24%), headache (16% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Local: Injection site: Tenderness (97% to 98%),  pain (27% to 41%), soreness (up to 16%), induration (5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: General aches (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Fever &ge;100&deg;F (2%), &gt;102&deg;F (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Pruritus (up to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Nausea (up to 8%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Local: Injection site: Erythema (up to 5%), swelling (up to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal pain, allergic reactions, anaphylaxis, arthralgia, cervical pain, diarrhea, dizziness, flu-like syndrome, Guillain-Barr&eacute; syndrome, hypotension, injection site inflammation (including angioedema and urticaria), loss of consciousness, lymphadenopathy, malaise, perforated jejunum, rash, serum sickness, tremor, urticaria, vasodilation, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Headache (5%), fever (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (6%), nausea (6%), diarrhea (3%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylactic reaction, demyelinating disease, myalgia, pain, RA, urticaria, sepsis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the vaccine. In addition, the oral vaccine is contraindicated with congenital or acquired immunodeficient state, acute febrile illness",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Typhoid fever: Should not be used to treat typhoid fever. Not all recipients of typhoid vaccine will be fully protected against typhoid fever. Travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Administer at least 2 weeks prior to expected exposure. Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use. May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids)); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: Full immunization schedule should be completed at least 1 week prior to expected exposure. The complete immunization schedule must be followed to achieve optimum immune response. Do not administer during acute GI illness; vaccination may be deferred with persistent diarrhea or vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antibiotics: May diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acetic Acid; Aluminum Acetate; Azithromycin (Ophthalmic); Bacitracin; Benzoin; Capreomycin; Ciprofloxacin (Ophthalmic); Clindamycin (Topical); Dapsone (Topical); Erythromycin (Ophthalmic); Erythromycin (Topical); Fidaxomicin; Gatifloxacin; Gentamicin (Ophthalmic); Gentamicin (Topical); Gentian Violet; Hexachlorophene; Mafenide; MetroNIDAZOLE (Topical); Neomycin; Oxychlorosene; Polymyxin B; Povidone-Iodine (Topical); Rifaximin; Silver Nitrate; Silver Sulfadiazine; Sulfacetamide (Ophthalmic); Sulfacetamide (Topical); Tobramycin (Ophthalmic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4039820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid alcohol within 2 hours of taking the capsule; may disrupt the enteric coating",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4039581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. The manufacturer of the Typhim Vi&reg; injection suggests delaying vaccination until the 2nd or 3rd trimester if possible. Untreated typhoid fever may lead to miscarriage or vertical intrauterine transmission causing neonatal typhoid (rare).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4039583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Typhim VI Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg/0.5 mL (0.5 mL): $74.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10166648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Typbar (TH);",
"     </li>",
"     <li>",
"      Typh-Vax (NZ);",
"     </li>",
"     <li>",
"      Typherix (HK, PH);",
"     </li>",
"     <li>",
"      Typhim VI (AU, BG, CL, CO, CR, DO, EE, FI, GT, HK, ID, KP, MY, NZ, PE, PH, PK, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Typhoral (IN);",
"     </li>",
"     <li>",
"      Typhovax (KP);",
"     </li>",
"     <li>",
"      Tyrix Vi (KP);",
"     </li>",
"     <li>",
"      Vivotif (DE, GB, IE);",
"     </li>",
"     <li>",
"      Vivotif Berna (AT, CH, DK, ES, HK, IT, KP, MY, NL, PH);",
"     </li>",
"     <li>",
"      Vivotif Berna Capsule (NO);",
"     </li>",
"     <li>",
"      Vivotif Oral (AU);",
"     </li>",
"     <li>",
"      Vivotif Oralt Vaccin (SE);",
"     </li>",
"     <li>",
"      Zerotyph (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Virulent strains of",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     cause disease by penetrating the intestinal mucosa and entering the systemic circulation via the lymphatic vasculature. One possible mechanism of conferring immunity may be the provocation of a local immune response in the intestinal tract induced by oral ingesting of a live strain with subsequent aborted infection. The ability of",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     to produce clinical disease (and to elicit an immune response) is dependent on the bacteria having a complete lipopolysaccharide. The live attenuate Ty21a strain lacks the enzyme UDP-4-galactose epimerase so that lipopolysaccharide is only synthesized under conditions that induce bacterial autolysis. Thus, the strain remains avirulent despite the production of sufficient lipopolysaccharide to evoke a protective immune response. Despite low levels of lipopolysaccharide synthesis, cells lyse before gaining a virulent phenotype due to the intracellular accumulation of metabolic intermediates.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immunity to",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     : Oral: ~1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immunity: Oral: ~4-7 years; Parenteral: Typhim Vi&reg;: &gt;17-21 months, Typherix&reg;: ~3 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Begier EM, Burewn DR, Haber P, et al, &ldquo;Postmarketing Safety Surveillance for Typhoid Fever Vaccines From the Vaccine Adverse Event Reporting System, July 1990 Through June 2002,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 38(6):771-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/14999618/pubmed\" id=\"14999618\" target=\"_blank\">",
"        14999618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Typhoid Immunization. Recommendations of the advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1994, 43(RR-14):1-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guzman CA, Borsutzky S, Griot-Wenk M, et al, &ldquo;Vaccines Against Typhoid Fever,&rdquo;",
"      <i>",
"       Vaccine",
"      </i>",
"      , 2006, 24(18):3804-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/16278037/pubmed\" id=\"16278037\" target=\"_blank\">",
"        16278037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parry CM, Hien TT, Dougan G, et al, &ldquo;Typhoid Fever,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(22):1770-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/12456854/pubmed\" id=\"12456854\" target=\"_blank\">",
"        12456854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/7/25718/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10030 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25718=[""].join("\n");
var outline_f25_7_25718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275259\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232378\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232371\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232374\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232372\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232355\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951008\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232358\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232356\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232376\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232346\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300191\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232350\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039820\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232352\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039581\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039583\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422285\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10166648\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539952\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232345\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232360\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/59/10161?source=related_link\">",
"      Typhoid vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/34/25125?source=related_link\">",
"      Typhoid vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_7_25719="Postoperative radiation therapy in the management of head and neck cancer";
var content_f25_7_25719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postoperative radiation therapy in the management of head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Shruti Jolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Avraham Eisbruch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Francis P Worden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25719/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/7/25719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected high-risk patients with head and neck squamous cell carcinoma receive postoperative radiation therapy (RT), with or without concurrent chemotherapy, following primary surgical resection with the aim of improving locoregional control and survival. The rationale for this approach is that RT may eradicate microscopic deposits of cancer cells that would progress and lead to a locoregional recurrence.",
"   </p>",
"   <p>",
"    Postoperative RT for head and neck cancer, alone and with concurrent chemotherapy, will be reviewed here. Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"       \"General principles of radiation therapy for head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to specific tumor sites, which are presented in detail in topics related to these tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H862126779\">",
"    <span class=\"h1\">",
"     FACTORS PREDICTIVE OF LOCOREGIONAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT is generally restricted to patients thought to be at elevated risk of locoregional recurrence. It should be used with caution and only in those at risk because of the morbidity of postoperative RT and uncertainty regarding a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/1\">",
"     1",
"    </a>",
"    ]. Factors associated with an increased risk of locoregional recurrence after surgery include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced tumor (T) stage",
"      <span class=\"nowrap\">",
"       (T3/T4)",
"      </span>",
"     </li>",
"     <li>",
"      Positive resection margins or tumor close to the resection margin",
"     </li>",
"     <li>",
"      Tumor extension through the lymph node capsule (extracapsular extension)",
"     </li>",
"     <li>",
"      Two or more positive lymph nodes",
"      <span class=\"nowrap\">",
"       (N2/N3)",
"      </span>",
"     </li>",
"     <li>",
"      Perineural invasion",
"     </li>",
"     <li>",
"      Lymphovascular space invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive margins and extracapsular extension are the two most unfavorable parameters, both of which are associated with significant increases in local recurrence and mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The definition of positive margins is not standardized; however, invasive tumor within 5 mm of the resection margin is commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/11\">",
"     11",
"    </a>",
"    ]. Metastases in a single ipsilateral lymph node, 3 cm or less in greatest dimension (ie, N1 lymph node stage) is not considered a high-risk feature in the absence of other adverse factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801220218\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE RT ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data supporting the use of postoperative RT without concurrent chemotherapy to improve locoregional control and survival is limited to two small randomized trials and retrospective observational data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial in 51 patients with advanced head and neck cancer found that the addition of RT to surgery decreased the overall recurrence rate [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/13\">",
"       13",
"      </a>",
"      ]. However, no difference in overall survival was observed.",
"     </li>",
"     <li>",
"      A second trial, limited to 140 patients, all with squamous cell carcinoma of the buccal mucosa, did observe a statistically significant increase in disease-free survival at three years with postoperative RT compared to surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective studies suggest that postoperative RT improves survival after surgery, although this benefit may be limited to carefully selected high-risk patients. As an example, a Surveillance, Epidemiology and End Results (SEER) database study analyzed outcomes in 8795 patients with lymph-node positive head and neck cancer diagnosed between 1988 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/15\">",
"     15",
"    </a>",
"    ]. All patients were treated with surgery and adjuvant RT (pre-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postoperatively) or surgery alone. On univariate analysis, the addition of adjuvant RT to surgery was associated with a significantly improved five-year overall survival (43.2 versus 33.4 percent) and cancer-specific survival (50.9 versus 42.1 percent). More detailed analyses of smaller series also support a role for adjuvant RT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    However, postoperative RT can cause important acute and late toxicity and is related to the dose of radiation. For example, in a series of patients treated with either lower dose (57.6 Gy over 6.5 weeks) or higher dose (63 Gy over five weeks) postoperative RT, confluent mucositis was present in the low and high dose cohorts in 5 and 47 percent of patients, and tube feeding was required in 12 and 39 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, the five-year actuarial rates of late grade 3 and 4 toxicity",
"    <span class=\"nowrap\">",
"     (ulcer/soft",
"    </span>",
"    tissue necrosis, fibrosis, dysphagia,",
"    <span class=\"nowrap\">",
"     fistula/osteonecrosis)",
"    </span>",
"    were 17 and 38 percent for the low and high dose groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CHEMORADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated that postoperative concurrent chemoradiation therapy is more likely than postoperative radiation therapy (RT) alone to control locoregional disease and improve disease-free survival for selected poor prognosis patients. Thus, we recommend postoperative concurrent chemoradiotherapy over postoperative RT alone for patients with positive surgical margins and extracapsular extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemoradiotherapy versus radiotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large cooperative group trials have compared adjuvant chemoradiotherapy with postoperative RT alone and provide insights into which patient subsets benefit from a combined approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the European Organization for Research and Treatment of Cancer (EORTC) trial 22931, 334 patients with resected high-risk head and neck cancer were randomly assigned to RT alone (66 Gy in 33 daily 2 Gy fractions) or the same dose with concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      on days 1, 22, and 43 of RT) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/17\">",
"       17",
"      </a>",
"      ]. High-risk disease was defined as a T3 or T4 primary with any nodal stage (except T3N0 laryngeal cancer), involved surgical margins, extracapsular extension, perineural invasion, vascular invasion, or oral",
"      <span class=\"nowrap\">",
"       cavity/oropharyngeal",
"      </span>",
"      primary sites with involvement of level IV or V lymph nodes. With a median follow-up of 60 months, postoperative concurrent chemoradiotherapy significantly improved five-year progression free survival, locoregional control, and overall survival compared with postoperative RT alone (47 versus 36 percent, 82 versus 69 percent, and 53 versus 40 percent, respectively).",
"     </li>",
"     <li>",
"      Radiation Therapy Oncology Group (RTOG) trial 9501 randomly assigned 459 patients with resected high-risk head and neck cancer to RT alone (60 to 66 Gy in 30 to 33 fractions) or the same doses of RT with concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      on days 1, 22, and 43 of RT) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/18\">",
"       18",
"      </a>",
"      ]. The definition of high risk was restricted to positive resection margins, involvement of two or more lymph nodes, or extracapsular nodal extension. With a median follow-up of 46 months, concurrent chemoradiotherapy significantly improved two-year locoregional control and disease-free survival compared with RT alone (82 versus 72 percent and 54 versus 45 percent, respectively). However, the increase in overall survival was not statistically significant (64 versus 57 percent).",
"      <br/>",
"      <br/>",
"      However, updated results at 10 years found that there were no statistically significant differences with chemoradiotherapy versus RT alone in locoregional failure (22 versus 29 percent), disease-free survival (20 versus 19 percent), or overall survival (29 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/19\">",
"       19",
"      </a>",
"      ]. There were statistically significant differences observed in patients with extracapsular spread or positive margins for locoregional control and disease-free survival and a trend for better overall survival in an unplanned subgroup analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both trials, the incidence of acute severe mucosal toxicity was significantly greater with postoperative concurrent chemoradiotherapy compared with RT alone (77 versus 34 percent in the EORTC trial), but late complications were comparable for both treatments.",
"   </p>",
"   <p>",
"    The failure of these two trials to reach the same conclusions, ie, that concurrent chemoradiotherapy improves locoregional control, disease-free survival, and overall survival, has been attributed to the different patient populations included in these two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. When comparative analyses were performed on pooled data from these trials (including selection criteria, clinical and pathologic risk factors, and treatment outcomes), extracapsular extension and microscopically involved surgical margins were the only risk factors for which the impact of postoperative concurrent chemoradiotherapy was significant in both trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consequently, we and others recommend postoperative concurrent chemoradiotherapy over postoperative RT alone primarily for patients with positive surgical margins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracapsular extension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Whether concurrent chemoradiotherapy should be routinely added to postoperative RT for patients with locoregionally advanced head and neck cancer and other adverse features is less clear. Patients considered to be at elevated risk for recurrence based upon perineural or vascular invasion, two or more involved lymph nodes, or T3 and T4 tumors are considered to be at intermediate risk and are commonly treated with postoperative RT alone. The RTOG 0920 trial is currently evaluating the benefit for the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to standard postoperative RT for patients with these intermediate risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Concurrent chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to the optimal chemotherapy regimen, although the evidence supports a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimen. As with definitive concurrent chemoradiotherapy, high-dose bolus cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, and 43) has the best established efficacy and is often considered the preferred regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    regimen is associated with considerable severe acute and late toxicities. In the EORTC and RTOG trials described above, only half of the patients were able to receive all three cycles with minimal treatment delays [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, there was no difference in two-year locoregional control in a subgroup analysis of patients in the RTOG trial who received chemotherapy exactly as planned in the protocol or with only minor variations compared to all patients assigned to concurrent chemoradiotherapy (82 percent for each) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/18\">",
"     18",
"    </a>",
"    ]. Consequently, some experts routinely give only two cycles of cisplatin concurrent with RT.",
"   </p>",
"   <p>",
"    To minimize toxicity, lower dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    regimens have also been used. Cisplatin (30 to 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) during RT is a commonly used option, especially for patients with a diminished performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice weekly) rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was used as the concurrent chemotherapy in a clinical trial of patients with lymph node-positive head and neck cancer, no significant improvement in locoregional control or overall survival was seen compared with RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/24\">",
"     24",
"    </a>",
"    ]. Whether this was due to the chemotherapy regimen or other factors, such as patient selection, is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Molecularly targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has established efficacy concurrent with RT in the primary treatment of locoregionally advanced head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027372#H281027372\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Epidermal growth factor inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the adjuvant setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    was combined with either low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) concurrently during postoperative RT in a phase II trial (RTOG 0234) of patients with positive margins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    two or more nodal metastases or extracapsular nodal extension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/25\">",
"     25",
"    </a>",
"    ]. This trial showed promising survival with moderate toxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is not the standard of care and should only be used as part of a post-operative adjuvant strategy in the context of a clinical trial. In an ongoing, randomized phase III trial (RTOG 0920), patients with locally-advanced, resected head and neck cancer are being treated with postoperative radiation therapy with or without cetuximab (NCT 01311063).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total dose, timing, and duration of therapy may all affect outcomes in patients with head and neck squamous cell carcinoma receiving postoperative radiation therapy (RT) or concurrent chemoradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/3,26\">",
"     3,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initiation and treatment delays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time interval between surgery and initiation of RT as well as the duration of postoperative RT also appear to have an impact on outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/3,26,27\">",
"     3,26,27",
"    </a>",
"    ]. Patients who begin RT more than six weeks after surgery are more likely to develop a local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/26\">",
"     26",
"    </a>",
"    ]. Locoregional control is also better for patients who complete postoperative RT within 100 days or less from the date of surgery compared with patients treated over a longer period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. In the absence of wound healing issues or medical contraindications, postoperative RT should be started no later than six weeks after surgery and should be completed in a timely manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dose and treatment volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment parameters of postoperative RT for head and neck cancer vary with the clinical and pathologic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493366803#H1493366803\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Dose and schedule of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a clinical trial that aimed to establish the optimal dosing for conventionally fractionated postoperative RT, patients were randomly assigned to one of three dose levels ranging from 52 to 68 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients treated with a dose of 54 Gy or less had a significantly higher primary failure rate compared with those treated with higher doses. No significant dose response was demonstrated at doses &gt;57.6 Gy except for patients with extracapsular nodal disease in the neck in whom the recurrence rate was significantly higher at 57.6 Gy than at 63 Gy. Consequently, patients with high-risk features who are not candidates for postoperative concurrent chemoradiotherapy are treated with higher doses (at least 63 Gy). Dose-response relationships are less well understood when concurrent chemotherapy is utilized, but most high-risk volumes typically receive doses &ge;60 Gy, in 2 Gy daily fractions.",
"   </p>",
"   <p>",
"    If all gross disease is resected (ie, negative margins) in patients with advanced primary lesions (T3-4), we recommend postoperative RT doses of at least 56 to 60 Gy to the primary tumor bed. For patients with microscopically positive margins or extracapsular extension, we recommend a 6 Gy boost in three fractions for a total dose of 66 Gy to that region. For those with grossly positive margins, the site of residual disease should be boosted to a total dose of 70 Gy.",
"   </p>",
"   <p>",
"    The neck is also included with postoperative RT. Subclinical regions (ie, clinically negative neck) that have not been operated are electively treated to 50 Gy in 25 fractions. Involved nodal regions receive 60 Gy in 30 fractions, and regions of extracapsular extension may receive an additional boost of 4 to 6 Gy in two to three fractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional postoperative RT schedules typically deliver 54 to 66 Gy in 2 Gy daily fractions, over five to seven weeks. Altered-fractionation RT schedules, including accelerated RT and hyperfractionation, have been investigated to overcome accelerated repopulation and to safely escalate the dose. These strategies when compared to conventional, once-daily RT have demonstrated improved locoregional control, but a survival benefit has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The added cost and logistical challenges of multiple fractions per day RT have limited their implementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H99325300#H99325300\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Hyperfractionation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493367204#H1493367204\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Accelerated fractionation RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiotherapy techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard approach for patients treated with postoperative RT is to use conventional fractionation external beam RT (EBRT) using three-dimensional conformal treatment planning (3D-CRT). Refinements, including intensity-modulated RT (IMRT) and image-guided RT (IGRT) are frequently used where available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'External beam radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment usually starts with large fields covering all areas at risk to 50 Gy, followed by shrinking fields. A final boost treatment to the primary tumor bed and neck regions with involved lymph nodes may be administered using either EBRT or brachytherapy.",
"   </p>",
"   <p>",
"    Retrospective studies suggest that a treatment boost with brachytherapy may improve local control for patients with positive tumor margins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, brachytherapy is used less frequently, since the majority of patients with positive margins typically receive chemotherapy concurrent with postoperative RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541274485\">",
"    <span class=\"h2\">",
"     Postoperative versus preoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is now used as an adjuvant almost exclusively in the postoperative period. Concerns about operating in an irradiated field, the poorer local control in one older trial, the ability to use pathologic findings to guide high-dose RT planning, and the use of functional organ preservation approaches (chemoradiotherapy) have led to the abandonment of pre-operative RT for head and neck cancer. In the RTOG 7303 trial, preoperative RT used a dose of 50 Gy and the local control was worse than postoperative radiotherapy with a dose of 70 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25719/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no difference in overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected patients with head and neck squamous cell carcinoma treated with primary surgical resection who are at high-risk for locoregional recurrence are treated with postoperative radiation therapy (RT), with or without concurrent chemotherapy, with the aim of improving locoregional control and survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have undergone surgery for locoregionally advanced head and neck cancer, we recommend postoperative RTfor those with the following high-risk features (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H862126779\">",
"       'Factors predictive of locoregional failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Advanced T-stage",
"      <span class=\"nowrap\">",
"       (T3/T4)",
"      </span>",
"     </li>",
"     <li>",
"      Positive or close margins",
"     </li>",
"     <li>",
"      Two or more positive lymph nodes",
"      <span class=\"nowrap\">",
"       (N2/N3)",
"      </span>",
"     </li>",
"     <li>",
"      Extracapsular nodal extension",
"     </li>",
"     <li>",
"      Perineural or lymphovascular invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend postoperative concurrent chemoradiation rather than postoperative RT alone for patients with positive surgical margins or extracapsular extension (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with a good performance status,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks) concurrent with RT is the best established regimen. Cisplatin (30 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) during RT is an option, especially for patients with a diminished performance status. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Postoperative chemoradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of wound healing issues or medical contraindications, postoperative RT should be started within six weeks after surgery and completed in a timely manner. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/1\">",
"      Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005; 10:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/2\">",
"      Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys 1992; 23:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/3\">",
"      Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/4\">",
"      Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993; 26:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/5\">",
"      Amdur RJ, Parsons JT, Mendenhall WM, et al. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys 1989; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/6\">",
"      Olsen KD, Caruso M, Foote RL, et al. Primary head and neck cancer. Histopathologic predictors of recurrence after neck dissection in patients with lymph node involvement. Arch Otolaryngol Head Neck Surg 1994; 120:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/7\">",
"      Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins. Int J Radiat Oncol Biol Phys 1993; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/8\">",
"      Jacobs JR, Ahmad K, Casiano R, et al. Implications of positive surgical margins. Laryngoscope 1993; 103:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/9\">",
"      Laramore GE, Scott CB, Schuller DE, et al. Is a surgical resection leaving positive margins of benefit to the patient with locally advanced squamous cell carcinoma of the head and neck: a comparative study using the intergroup study 0034 and the Radiation Therapy Oncology Group head and neck database. Int J Radiat Oncol Biol Phys 1993; 27:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/10\">",
"      Looser KG, Shah JP, Strong EW. The significance of \"positive\" margins in surgically resected epidermoid carcinomas. Head Neck Surg 1978; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/11\">",
"      Meier JD, Oliver DA, Varvares MA. Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey. Head Neck 2005; 27:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/12\">",
"      J&auml;ckel MC, Ambrosch P, Christiansen H, et al. Value of postoperative radiotherapy in patients with pathologic N1 neck disease. Head Neck 2008; 30:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/13\">",
"      Kokal WA, Neifeld JP, Eisert D, et al. Postoperative radiation as adjuvant treatment for carcinoma of the oral cavity, larynx, and pharynx: preliminary report of a prospective randomized trial. J Surg Oncol 1988; 38:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/14\">",
"      Mishra RC, Singh DN, Mishra TK. Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial. Eur J Surg Oncol 1996; 22:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/15\">",
"      Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 2008; 112:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/16\">",
"      Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998; 40:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/17\">",
"      Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/18\">",
"      Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/19\">",
"      Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/20\">",
"      Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27:843.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/22\">",
"      Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/23\">",
"      Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma. Cancer 2009; 115:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/24\">",
"      Racadot S, Mercier M, Dussart S, et al. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiother Oncol 2008; 87:164.",
"     </a>",
"    </li>",
"    <li>",
"     Kies MS, Harris J, Rotman MZ, et al. Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234). Int J Radiat Oncol Biol Phys 2009; 75:S14. (Available online at file://www.redjournal.org/article/S0360-3016(09)01099-2/fulltext, accessed January 5, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/26\">",
"      Mantravadi RV, Haas RE, Liebner EJ, et al. Postoperative radiotherapy for persistent tumor at the surgical margin in head and neck cancers. Laryngoscope 1983; 93:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/27\">",
"      Parsons JT, Mendenhall WM, Stringer SP, et al. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 1997; 39:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/28\">",
"      Awwad HK, Lotayef M, Shouman T, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 2002; 86:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/29\">",
"      Shah N, Saunders MI, Dische S. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. Clin Oncol (R Coll Radiol) 2000; 12:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/30\">",
"      Trotti A, Klotch D, Endicott J, et al. A prospective trial of accelerated radiotherapy in the postoperative treatment of high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1993; 26:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/31\">",
"      Chao KS, Emami B, Akhileswaran R, et al. The impact of surgical margin status and use of an interstitial implant on T1, T2 oral tongue cancers after surgery. Int J Radiat Oncol Biol Phys 1996; 36:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/32\">",
"      Beitler JJ, Smith RV, Silver CE, et al. Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control. Int J Radiat Oncol Biol Phys 1998; 40:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25719/abstract/33\">",
"      Marcial VA, Pajak TF, Kramer S, et al. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin Oncol 1988; 15:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3374 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25719=[""].join("\n");
var outline_f25_7_25719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H862126779\">",
"      FACTORS PREDICTIVE OF LOCOREGIONAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801220218\">",
"      POSTOPERATIVE RT ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POSTOPERATIVE CHEMORADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemoradiotherapy versus radiotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Concurrent chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initiation and treatment delays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dose and treatment volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiotherapy techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541274485\">",
"      Postoperative versus preoperative RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_7_25720="Bilateral laminar fractures of cervical spine";
var content_f25_7_25720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Bilateral laminar fractures of cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 579px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiograph (A) demonstrates posterior impaction with multiple comminuted laminar and spinous processes fractures from C2 to C6 (white arrows). The acute vacuum disc (black arrow) with abnormal widening of the anterior C6-7 disc space is a sign of anterior and middle column distraction. The corresponding CT images (B and C) demonstrate displacement of the spinous processes and bilateral comminuted laminar fractures (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schwartz ED, Flander AE. Spinal Trauma: Imaging, Diagnosis, and Management, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25720=[""].join("\n");
var outline_f25_7_25720=null;
var title_f25_7_25721="The role of the vulnerable plaque in acute coronary syndromes";
var content_f25_7_25721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of the vulnerable plaque in acute coronary syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Fumiyuki Otsuka, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Frank Kolodgie, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Renu Virmani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Peter Libby, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25721/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/7/25721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13452767\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary syndromes (ACS) represent a spectrum in the clinical manifestations of acute coronary artery disease that includes unstable angina, acute myocardial infarction, and sudden coronary arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\", section on 'Myocardial ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary artery thrombosis is the final pathogenic mechanism of most cases with ACS, as documented by angiographic and pathologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For example, coronary artery thrombi are found in 50 to 75 percent of cases of sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The formation of an intraluminal clot is thought to result from the loss of integrity of a protective covering over an atherosclerotic plaque. In healthy arteries, a single layer of endothelial cells separates the blood from potentially thrombogenic components of the arterial medial layer, both of which are referred to as vulnerable plaques. The loss of integrity of the protective covering occurs with processes called plaque rupture or erosion. This disruption allows blood to come in contact with the highly thrombogenic contents of the necrotic core of the plaque and luminal thrombosis to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Intraluminal thrombosis after exposure of blood to calcified nodules has also been observed. Other mechanisms of ACS, such as a supply-demand mismatch, have been postulated.",
"   </p>",
"   <p>",
"    Plaque rupture or erosion often occurs at sites where luminal stenosis is angiographically modest [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Autopsy studies of sudden coronary death victims have shown that approximately 40 percent of plaque ruptures occur at lesion sites with less than 50 percent diameter stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/7\">",
"     7",
"    </a>",
"    ]. In instances when rupture or erosion does not lead to thrombotic occlusion of the vessel, each event may not necessarily cause symptoms and plaque healing with progression may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic focuses on the contribution of plaque rupture to the development of acute coronary syndromes as well as potential strategies to detect and treat vulnerable plaques. The underlying pathology and pathogenesis of coronary plaque progression, including rupture, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452783\">",
"    <span class=\"h1\">",
"     PLAQUE FEATURES RESPONSIBLE FOR ACUTE THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intraluminal thrombosis is characterized by layered platelet aggregates with variable amounts of fibrin, red blood cells, and acute inflammatory cells. Insights into the mechanisms of coronary thrombosis have come from detailed analyses of plaque morphologies in cases of sudden death and acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3,10-15\">",
"     3,10-15",
"    </a>",
"    ]. Pathogenic mechanisms responsible for acute coronary thrombosis are plaque rupture, plaque erosion, and calcified nodules (",
"    <a class=\"graphic graphic_figure graphicRef72618 \" href=\"UTD.htm?43/17/44311\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452790\">",
"    <span class=\"h2\">",
"     Plaque rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque rupture is the most common morphology associated with acute coronary thrombosis (",
"    <a class=\"graphic graphic_figure graphicRef72618 \" href=\"UTD.htm?43/17/44311\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71847 \" href=\"UTD.htm?14/44/15050\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80581 \" href=\"UTD.htm?23/15/23799\">",
"     figure 3",
"    </a>",
"    ).The morphology of plaque rupture shows an intraluminal thrombus overlying a thin disrupted fibrous cap covering a atherosclerotic plaque. The cap is infiltrated by macrophages and T-lymphocytes on an advanced lesion with a relatively large necrotic core (",
"    <a class=\"graphic graphic_picture graphicRef61067 \" href=\"UTD.htm?36/40/37514\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3\">",
"     3",
"    </a>",
"    ]. The fibrous cap consists mainly of type I collagen with varying degrees of macrophages and lymphocytes, whereas the smooth muscle cells component within the cap is absent or sparse. Although it is widely accepted that fibrous cap rupture occurs at its weakest point often near shoulder regions, autopsy studies using serially cut sections demonstrate an equal number of ruptures occurring at the mid-portion of the fibrous cap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link&amp;anchor=H13450322#H13450322\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Thin-cap fibroatheroma (vulnerable plaque)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A breach in the fibrous cap allows circulating cellular and noncellular elements of blood to come in direct contact with the highly thrombogenic components of the necrotic core and is thought directly responsible for the actual development of the thrombus. Historically, the necrotic core was thought to be the main source of the tissue factor; however, it is now believed that circulating monocytes, instead of macrophages alone, supply tissue factor that trigger and propagate acute thrombi overlying unstable coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/16\">",
"     16",
"    </a>",
"    ]. At the rupture site, the luminal thrombus often is platelet-rich thereby giving rise to a grossly white appearance (white thrombus), while at the proximal and distal ends near the sites of propagation it appears red (red thrombus) as it is composed of layers of fibrin and red blood cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link&amp;anchor=H2#H2\">",
"     \"The role of platelets in coronary heart disease\", section on 'Platelet adhesion and aggregation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76054075\">",
"    <span class=\"h2\">",
"     Plaque erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque erosion represents the second most prevalent underlying morphology of acute coronary thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link&amp;anchor=H13450341#H13450341\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Plaque erosion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics of the overlying thrombus differ significantly from those seen with in patients with plaque rupture. Autopsy studies of sudden death victims have shown that greater than 85 percent of thrombi in erosions exhibited late stages of healing characterized by inflammatory cell lysis, invasion by smooth muscle cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endothelial cells, or organized layers of smooth muscle cells and proteoglycans with varying degrees of",
"    <span class=\"nowrap\">",
"     platelet/fibrin",
"    </span>",
"    layering, whereas in ruptures only one-half of thrombi show healing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postmortem studies have shown that coronary thrombi superimposed on eroded plaques contain a higher density of myeloperoxidase-positive cells than thrombi superimposed on ruptured plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/18\">",
"     18",
"    </a>",
"    ]. Systemic myeloperoxidase levels are also elevated in patients with acute coronary syndromes presenting with eroded plaque as compared to those presenting with rupture, suggesting that elevations in selective inflammatory biomarkers may reflect specific acute coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intense accumulation of extracellular matrix molecules such as hyaluronan and versican (proteoglycan) are observed at the sites of plaque erosion whereas there is relatively little accumulation of proteoglycans and hyaluronan at plaque rupture sites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/19\">",
"     19",
"    </a>",
"    ]. It is hypothesized that a selective accumulation of hyaluronan in eroded plaques may promote the de-endothelialization and platelet aggregation. Hyaluronan can directly promote the polymerization of fibrin, which may facilitate smooth muscle cell migration and plaque progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452804\">",
"    <span class=\"h2\">",
"     Calcified nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcified nodule represents the least frequent underlying pathology of luminal thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3\">",
"     3",
"    </a>",
"    ]. This term is reserved for fibrocalcific plaques with little or no underlying necrotic core with disruption of the luminal surface and thrombosis attributed to eruptive dense calcified nodules (",
"    <a class=\"graphic graphic_figure graphicRef72618 \" href=\"UTD.htm?43/17/44311\">",
"     figure 1",
"    </a>",
"    ). These occur in heavily calcified arteries and often show large plates of calcified matrix with surrounding areas of fibrosis, inflammation, and neovascularization. Although the precise nature of this lesion remains incompletely understood, fragmentation of the calcified plates can contribute to the nodular calcification where even sometimes bone formation can be observed with interspersed fibrin. These lesions are generally more prevalent in older males with tortuous coronary arteries, and chronic renal failure. The calcified nodule erodes into the lumen and the overlying collagen is thinned along with endothelial loss allowing the bare calcium to be in contact with the flowing blood and thrombus formation to occur.",
"   </p>",
"   <p>",
"    Additional information about the prevalence, distribution, and outcomes of patients with calcified nodules comes from PROSPECT study (see",
"    <a class=\"local\" href=\"#H13452912\">",
"     'Natural history'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/20\">",
"     20",
"    </a>",
"    ]. Three-vessel gray-scale and virtual histology intravascular ultrasound (IVUS) was performed in the proximal-mid segments of all three coronary arteries in 697 patients with ACS who underwent stenting. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, 314 nodules were found in 250 of 1573 analyzable arteries, with a prevalence of 17 percent per artery and 30 percent per patient. Two or more nodules were found in 3 percent of arteries and 12 percent of patients.",
"     </li>",
"     <li>",
"      The calcified nodules were located &lt;40 mm from the ostium of the coronary artery in about 85 percent of the left anterior descending and left circumflex arteries; they were more evenly distributed along the length of the right coronary arteries.",
"     </li>",
"     <li>",
"      Patients with calcified nodules were significantly older and had more plaque volume and thick-cap atheroma.",
"     </li>",
"     <li>",
"      Patients with calcified nodules had fewer cumulative major non-culprit adverse events during a median follow-up of three years (7 versus 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caution must be exercised, however, when interpreting these results, as most of the IVUS-detected calcified nodules in this study do not have thrombus, whereas the previously reported calcified nodules in the pathologic studies require the presence of luminal thrombus. &ldquo;Non-thrombotic calcified nodules&rdquo; should have been discriminated from &ldquo;calcified nodules&rdquo;, and the non-thrombotic calcified nodules have been described as &ldquo;nodular calcification&rdquo; by our group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3\">",
"     3",
"    </a>",
"    ]. In the PROSPECT study, patients with &ldquo;IVUS-detected nodular calcification&rdquo; had fewer cardiac events than those without, suggesting that these lesions are not high-risk plaques predictive of future events. However, prognostic significance of identifying &ldquo;calcified nodules&rdquo; and &ldquo;nodular calcification&rdquo; should be confirmed by future studies utilizing other imaging modalities that enable more accurate detection of thrombus and nodules of calcification. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452847\">",
"    <span class=\"h1\">",
"     PLAQUE MORPHOLOGY IN ACUTE CORONARY SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452854\">",
"    <span class=\"h2\">",
"     Sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In autopsy studies of patients with sudden cardiac death, thrombus has been reported in 50 to 75 percent of cases. The underlying pathologic lesions are plaque rupture (55 to 65 percent), erosion (30 to 40 percent for erosion), and calcified nodules (2 to 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3,10-14\">",
"     3,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452861\">",
"    <span class=\"h2\">",
"     Acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute ST-segment elevation myocardial infarction (STEMI), an autopsy has shown that approximately 75 percent of cases are due to plaque rupture, and remaining 25 percent are attributed to plaque erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/15\">",
"     15",
"    </a>",
"    ]. This finding has been confirmed by clinical studies utilizing high-resolution (10-15 &mu;m) imaging modality optical coherence tomography (OCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/21\">",
"     21",
"    </a>",
"    ]. In non-ST-segment elevation acute coronary syndromes using OCT, plaque rupture was in 47 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/22\">",
"     22",
"    </a>",
"    ]. Studies using intravascular ultrasound (IVUS) also report an incidence of plaque rupture more frequently in patients with STEMI than in those with non-ST elevation myocardial infarction (NSTEMI) (46 versus 29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/23\">",
"     23",
"    </a>",
"    ]. One OCT study has reported that the incidence of plaque rupture in",
"    <span class=\"nowrap\">",
"     NSTEMI/unstable",
"    </span>",
"    angina is 47 percent, whereas in STEMI it is 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link&amp;anchor=H321552326#H321552326\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\", section on 'Optical coherence tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452869\">",
"    <span class=\"h2\">",
"     Unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of plaque rupture in unstable angina is lower than with sudden cardiac death or acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a quantitative comparison of the amount of narrowing by atherosclerotic plaques in the major epicardial coronary arteries at autopsy in cases of sudden coronary death, acute myocardial infarction, and unstable angina, each of the major epicardial coronary arteries was divided into 5-mm long segments and histologic sections were prepared for each of the 4016 segments from 80 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. The proportion of severe cross-sectional area narrowing (&gt;75 percent) was greatest in unstable angina (48 percent) as compared to sudden coronary death (36 percent) and acute myocardial infarction (34 percent). These findings suggest that patients with fatal unstable angina have more extensive severe narrowing than those with sudden coronary death or acute myocardial infarction. However, the fact that unstable angina patients had more severe stenoses does not necessarily mean that acute thrombosis was not the immediate cause of acute events including death. These studies date back to the time when saphenous vein graft was the main treatment for symptomatic coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/27\">",
"     27",
"    </a>",
"    ]. However, today most patients with angina do not die acutely from their disease. Many patients die of heart failure as a result of ischemic cardiomyopathy. Some, in whom angina has stabilized die of extracardiac causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452876\">",
"    <span class=\"h2\">",
"     Age and sex differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies in both sudden coronary death and acute myocardial infarction have revealed that plaque erosion is the primary lesion in patients under the age of 50 years and premenopausal women. In women older than 50 years, 80 percent of coronary thrombi occur from plaque rupture; when they occur in women younger than 50 years, there is a strong association with hyperlipidemia.",
"   </p>",
"   <p>",
"    Although plaque ruptures occur in men of all ages, their relative incidence in sudden coronary death decreases with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174918233\">",
"    <span class=\"h2\">",
"     Other correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In deaths attributed to plaque rupture, approximately 70 percent of cases show the presence of thin-cap fibroatheromas remote from the actual rupture site. On the contrary, the incidence of thin-cap fibroatheromas is markedly less (30 percent) where deaths are associated with flow limiting stenosis, or erosions.",
"   </p>",
"   <p>",
"    The majority of thin-cap fibroatheromas occur predominantly in the proximal portion of the three major coronary arteries; the proximal portion of the left anterior descending artery is the most frequent location (43 percent) followed by the proximal right coronary artery (20 percent) and left circumflex artery (18 percent) in acute coronary syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174918240\">",
"    <span class=\"h2\">",
"     Repeat plaque ruptures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque rupture with luminal thrombus may lead to ischemic symptoms. Total occlusion is often detected as ST-segment elevation on electrocardiogram, while nonocclusive thrombosis may result in non-ST-segment elevation myocardial infarction or unstable angina. While plaque rupture may lead to either death or myocardial infarction, a single episode may occur without causing symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/8\">",
"     8",
"    </a>",
"    ]. Plaque rupture with healing may be a repeated event at the same location. The lesion may exhibit multiple layers of necrotic cores separated by layers of collagen. These repeated thrombotic events contribute to gradual luminal narrowing and plaque progression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/8\">",
"     8",
"    </a>",
"    ]. This significant increase in plaque burden and luminal narrowing due to previous repeated thrombosis usually occurs in the absence of cardiac symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link&amp;anchor=H13450356#H13450356\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Healed rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of silent episodes of rupture is unknown. Autopsy data showed that 61 percent of hearts from sudden coronary death victims have healed plaque ruptures, where the incidence is around 80 percent in stable plaques with severe stenosis, and 75 percent in plaque rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/8\">",
"     8",
"    </a>",
"    ]. The frequency of healed plaque ruptures increases in proportion with luminal narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452883\">",
"    <span class=\"h1\">",
"     OBSERVATIONS IN PATIENTS WITH PLAQUE RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque rupture has been thought to be present when coronary angiography show complex lesions, which consist of stenosis with irregular, rough borders, and ulceration with or without intraluminal filling defects suggestive of a thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The presence of angiographic complex lesions is associated with rapid progression of coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A substantial proportion (40 percent) of patients with acute myocardial infarction have angiographic evidence of multiple complex lesions; this has been termed &ldquo;multiple plaque instability&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/36\">",
"     36",
"    </a>",
"    ]. This situation is associated with adverse clinical outcomes. Angioscopic studies support this concept, by showing the presence of multiple yellow plaques, ie, vulnerable plaques, throughout the coronary-tree in patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, three-vessel intravascular ultrasound (IVUS) imaging demonstrated that culprit plaque rupture, remote plaque rupture, and multiple plaque rupture were all more frequent in patients with acute myocardial infarction as compared to those with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/38\">",
"     38",
"    </a>",
"    ]. However, in morphologic autopsy studies the incidence of multiple rupture sites in an individual is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical studies utilizing IVUS have shown that the presence of plaque rupture in patients with acute myocardial infarction is associated with increased C-reactive protein levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Moreover, in patients with first anterior acute myocardial infarction (STEMI), IVUS-identified plaque rupture was seen in 59 percent of cases while no such rupture was identified in the rest (41 percent). The vessel with rupture had larger size and had greater positive remodeling and led to larger infarct size and a higher incidence of no-reflow phenomenon following percutaneous coronary intervention as compared to those without rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/42\">",
"     42",
"    </a>",
"    ]. This finding suggests that if plaque rupture is identified by IVUS it is more likely that the patients will have greater biomarker rise and a larger infarct and that the necrotic core is more likely to embolize because of greater vessel size and necrotic core that is responsible for the no-reflow phenomenon.",
"   </p>",
"   <p>",
"    An optical coherence tomography study in patients with acute coronary syndromes with plaque rupture has revealed that the site of plaque rupture at the shoulder was more frequently observed in patients with exertion-triggered symptom onset (93 percent) as compared to those with rest-onset (57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/43\">",
"     43",
"    </a>",
"    ]. This study also showed that the median value of disrupted fibrous cap thickness was significantly greater in exertion-triggered plaque rupture (90 &micro;m) than rest-onset plaque rupture (50 &micro;m) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/43\">",
"     43",
"    </a>",
"    ]. However, autopsy studies of sudden coronary death have shown that there were borderline difference in mean minimum thickness of fibrous cap between plaque ruptures associated with exertion (5.6 &micro;m) and those not related to exertion (9.9 &micro;m), while no difference was observed for mean maximal thickness of the fibrous cap (exertion; 27.9 versus rest; 30.8 &micro;m) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the relationship between fibrous cap thickness and the mechanism of plaque rupture may be multifactorial and remains poorly understood.",
"   </p>",
"   <p>",
"    In patients with STEMI who were treated with fibrinolysis, patients with impaired coronary flow (Thrombolysis In Myocardial Infarction [TIMI] flow grade &le;2) had a higher incidence of plaque rupture as detected by OCT than those with TIMI flow grade 3 (70 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, mean minimal fibrous cap thickness was significantly less in patients with TIMI flow grade &le;2 as compared to those with TIMI flow grade 3 (48 versus 87 &micro;m), and minimal cap thickness was an independent determinant of TIMI flow grade [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/44\">",
"     44",
"    </a>",
"    ]. This study suggests that the morphological characteristics of the culprit lesion in STEMI are associated with coronary flow after thrombolysis and may be related to the thrombus burden prior to fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452891\">",
"    <span class=\"h1\">",
"     VULNERABLE PLAQUES AND FUTURE RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since plaque rupture accounts for approximately 55 to 75 percent of acute thrombi in patients with acute coronary syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/3,15,21,22\">",
"     3,15,21,22",
"    </a>",
"    ], early recognition of the thin-cap fibroatheroma might lead to early treatment of potentially fatal lesions.",
"   </p>",
"   <p>",
"    Extensive efforts have been devoted to identify these rupture-prone &ldquo;vulnerable plaques.&rdquo; Recent advances in imaging technologies allow us to evaluate several morphologic features of coronary plaques in relation to the development of acute coronary syndromes in vivo, whereas the strategies to detect and treat vulnerable plaques for the prevention of plaque rupture need further refinements.",
"   </p>",
"   <p>",
"    Retrospective studies have shown that most atherosclerotic plaques responsible for future acute coronary events have angiographically non-critical stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This phenomenon can be partly explained by positive arterial remodeling, which may represent one important feature for detecting lesion vulnerability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The absence of severe narrowing in rupture-prone plaques, as well as the lack of ability to detect vulnerable morphologic features by means of angiography, has lead to the use of various newer imaging modalities to identify vulnerable plaques. Several relevant studies from the perspective of preventing plaque rupture will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452905\">",
"    <span class=\"h2\">",
"     Identification of vulnerable plaque by CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) angiography is emerging as a promising approach for the noninvasive assessment of coronary artery stenosis and plaque characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/47-51\">",
"     47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One clinical study has reported a potential usefulness of CT angiography to identify vulnerable plaques that have not yet ruptured in patients who have not experienced an acute coronary event [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/52\">",
"     52",
"    </a>",
"    ]. Among a total of 1059 patients who underwent CT angiography, two important CT characteristics, positive remodeling and low-attenuation plaque, were identified in 45 patients, and in another 27 patients only one feature was present. Of the 45 patients with these two characteristics, 10 (22.2 percent) developed acute coronary syndromes over a mean follow-up of 27 months, whereas one patient (3.7 percent) with a single feature developed acute coronary syndromes. In contrast, of the 820 patients who were negative for both features, only four (0.5 percent) developed acute coronary syndromes. This study suggests that coronary lesions showing both positive remodeling and low-attenuation plaques on CT angiography are at a higher risk of future acute coronary events.",
"   </p>",
"   <p>",
"    Considering the radiation exposure, use of contrast media, and cost, CT angiography is not recommended for screening. However, recent advances in CT technology employing a larger number of slices, prospective ECG-gating scan, and dual-source CT may diminish limitations of this technology and facilitate its application for screening as well as risk assessment of acute coronary syndromes in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452912\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the thin-cap fibroatheroma has been thought to be a precursor lesion of acute plaque rupture, prospective evaluation of the natural-history of thin-cap fibroatheromas has not been achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=see_link&amp;anchor=H13450322#H13450322\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\", section on 'Thin-cap fibroatheroma (vulnerable plaque)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study was conducted as a prospective, multi-center study, in which 697 patients with acute coronary syndromes were enrolled. These patients underwent three-vessel coronary angiography and gray-scale and radiofrequency intravascular ultrasonographic imaging after percutaneous coronary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three-year cumulative rate of major adverse cardiovascular events (death from cardiac causes, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or progressive angina) was equally attributable to recurrence at the site of culprit lesions (13 percent) as well as to nonculprit lesions (12 percent). Multivariate analysis showed that a baseline plaque burden of 70 percent or greater, a minimal luminal area of 4.0 mm",
"    <sup>",
"     2",
"    </sup>",
"    or less, and the presence of thin-cap fibroatheroma as detected by radiofrequency intravascular ultrasonography were independent predictors of subsequent non-culprit-related major adverse cardiovascular events.",
"   </p>",
"   <p>",
"    However, among 595 thin-cap fibroatheromas in non-culprit lesions at baseline, the major adverse cardiovascular events occurred in only 26 lesions at a median follow-up of 3.4 years (estimated Kaplan-Meier event rate, 4.9 percent). Even when all three predictors described above were present, the event rate increased to only 18.2 percent.",
"   </p>",
"   <p>",
"    A serial virtual histology (VH)-IVUS study (a proposed method for tissue characterization based on analysis of radiofrequency signals from the IVUS) has demonstrated that most thin-cap fibroatheromas as detected by VH-IVUS healed during 12-month follow-up, whereas new thin-cap fibroatheromas also developed overtime [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/54\">",
"     54",
"    </a>",
"    ]. Given the dynamic nature of coronary atherosclerosis as shown by this serial VH-IVUS study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/54\">",
"     54",
"    </a>",
"    ], it is possible that some thin-cap fibroatheromas at baseline in the PROSPECT study could have changed to thick-cap fibroatheromas during the follow-up period and conversely, some atherosclerotic lesions which were not detected as thin-cap fibroatheromas at baseline may have evolved overtime. Nevertheless, the results of the PROSPECT study suggest that the risk of plaque rupture in thin-cap fibroatheroma may not be high, and that refinements of strategies to detect and treat vulnerable plaques at higher risk for thrombotic complications are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link&amp;anchor=H321553541#H321553541\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\", section on 'Intravascular ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174916746\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND FATAL PLAQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia, smoking, diabetes mellitus, and hypertension are associated with atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plaque rupture is correlated with high total cholesterol (TC), low high-density lipoprotein cholesterol (HDL-C), and an elevated",
"    <span class=\"nowrap\">",
"     TC/HDL-C",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/13\">",
"     13",
"    </a>",
"    ]. Further, a rise in levels of TC correlated with an increase in the number of thin-cap fibroatheromas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/4\">",
"     4",
"    </a>",
"    ]. However the presence of acute thrombosis in sudden coronary death is associated with smoking regardless of rupture or erosion.",
"   </p>",
"   <p>",
"    In women, the incidence of plaque erosion correlates highly with smoking and is found with a greater frequency in individuals younger than 50 years. By contrast, plaque rupture is more prevalent in women older than 50 years and is associated with elevated TC levels and an increased incidence of thin-cap fibroatheromas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moreover, high-sensitivity C-reactive protein (hs-CRP) level is significantly elevated in patients dying suddenly with severe coronary artery disease, both with and without acute coronary thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/55\">",
"     55",
"    </a>",
"    ]. Serum level of hs-CRP correlates positively with its presence in plaques and is also a predictor of increase in the number of thin-cap fibroatheromas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/55\">",
"     55",
"    </a>",
"    ]. Lipoprotein-associated phospholipase A2 (Lp-PLA",
"    <sub>",
"     2",
"    </sub>",
"    ) represents an emerging biomarker with prognosticative value of cardiovascular risk, which is produced by inflammatory cells, bound to LDL and other lipoproteins, and facilitates the hydrolysis of phospholipids in the arterial wall.",
"    <strong>",
"    </strong>",
"    Lp-PLA2 may participate in the development of atherosclerosis and is found in vulnerable human plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/56\">",
"     56",
"    </a>",
"    ]. Elevated serum levels of Lp-PLA",
"    <sub>",
"     2",
"    </sub>",
"    have been associated with increased cardiovascular risk in healthy populations and in patients with identified vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452919\">",
"    <span class=\"h1\">",
"     STATIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that atherosclerosis is a systemic disease, medical treatment, rather than local stenting alone may to be a plausible approach to treat vulnerable plaques and reduce the risk of acute coronary events. For a variety of reasons, statin therapy may be useful in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is limited evidence to support statins can stabilize atheromatous vulnerable plaques.",
"   </p>",
"   <p>",
"    Previous studies in experimental animals have shown that statins increase fibrous cap thickness in association with collagen accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/62\">",
"     62",
"    </a>",
"    ], and reduce the number of inflammatory cells as well as various inflammatory mediators in atheromatous plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/63\">",
"     63",
"    </a>",
"    ]. In fact, an experimental study of apolipoprotein E-knockout mice has demonstrated that statin treatment reduces the incidence of plaque rupture in the brachiocephalic arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, a serial angioscopic study has shown that statin treatment results in changes in coronary plaque color, ie, reduction in yellow plaques, in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/65\">",
"     65",
"    </a>",
"    ]. A gray-scale IVUS study revealed that statins increase plaque hyperechogenicity without significantly decreasing plaque volume [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/66\">",
"     66",
"    </a>",
"    ], and a reduction in the lipid component of coronary plaques after statin treatment was demonstrated by a three-dimensional integrated backscatter IVUS study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/67\">",
"     67",
"    </a>",
"    ]. Another IVUS study has also reported that long-term statin treatment before the onset of STEMI is significantly associated with a lower incidence of plaque rupture as compared to the absence of statin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/68\">",
"     68",
"    </a>",
"    ]. Moreover, an OCT study has demonstrated that nine months of statin treatment increases fibrous cap thickness in nonculprit coronary plaques of patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25721/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13452933\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plaque rupture is an established cause of acute coronary syndromes and is the most common morphology associated with acute coronary thrombosis. Other etiologies include plaque erosion and calcified nodules. (See",
"      <a class=\"local\" href=\"#H13452783\">",
"       'Plaque features responsible for acute thrombosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Plaque rupture is seen in approximately 75 percent of cases of acute myocardial infarction, with a higher incidence in men than women. (See",
"      <a class=\"local\" href=\"#H13452783\">",
"       'Plaque features responsible for acute thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraluminal thrombus is often seen at the site of plaque rupture and is the likely immediate mechanism for acute myocardial infarction. The frequency of the coronary lesions with thrombi is 55 to 65 percent for ruptures, 30 to 40 percent for erosions, and 2 to 7 percent with calcified nodules in sudden coronary death victims. (See",
"      <a class=\"local\" href=\"#H13452847\">",
"       'Plaque morphology in acute coronary syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plaque rupture can develop without causing symptoms.",
"     </li>",
"     <li>",
"      Plaque rupture may develop at the sites with angiographically modest luminal stenoses, which has led to the use of various imaging modalities to identify rupture-prone &ldquo;vulnerable plaques&rdquo; characterized by thin-fibrous cap thickness and large necrotic core as well as positive arterial remodeling.",
"     </li>",
"     <li>",
"      Refinements of strategies to detect and predict which vulnerable plaques are at higher risk of rupture, as well as biomarkers that can better predict future coronary events are needed.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/1\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/2\">",
"      Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/3\">",
"      Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/4\">",
"      Burke AP, Farb A, Malcom GT, et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/5\">",
"      Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/6\">",
"      Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/7\">",
"      Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/8\">",
"      Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/9\">",
"      Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/10\">",
"      Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/11\">",
"      el Fawal MA, Berg GA, Wheatley DJ, Harland WA. Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. Br Heart J 1987; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/12\">",
"      Davies MJ, Bland JM, Hangartner JR, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/13\">",
"      Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/14\">",
"      Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/15\">",
"      Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999; 82:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/16\">",
"      Nemerson Y. A simple experiment and a weakening paradigm: the contribution of blood to propensity for thrombus formation. Arterioscler Thromb Vasc Biol 2002; 22:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/17\">",
"      Kramer MC, Rittersma SZ, de Winter RJ, et al. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Coll Cardiol 2010; 55:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/18\">",
"      Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 2010; 122:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/19\">",
"      Kolodgie FD, Burke AP, Farb A, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 2002; 22:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/20\">",
"      Xu Y, Mintz GS, Tam A, et al. Prevalence, distribution, predictors, and outcomes of patients with calcified nodules in native coronary arteries: a 3-vessel intravascular ultrasound analysis from Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT). Circulation 2012; 126:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/21\">",
"      Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007; 50:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/22\">",
"      Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv 2011; 4:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/23\">",
"      Hong YJ, Jeong MH, Choi YH, et al. Differences in intravascular ultrasound findings in culprit lesions in infarct-related arteries between ST segment elevation myocardial infarction and non-ST segment elevation myocardial infarction. J Cardiol 2010; 56:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/24\">",
"      Roberts WC, Kragel AH, Gertz SD, Roberts CS. Coronary arteries in unstable angina pectoris, acute myocardial infarction, and sudden coronary death. Am Heart J 1994; 127:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/25\">",
"      Kragel AH, Gertz SD, Roberts WC. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol 1991; 18:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/26\">",
"      Roberts WC. Qualitative and quantitative comparison of amounts of narrowing by atherosclerotic plaques in the major epicardial coronary arteries at necropsy in sudden coronary death, transmural acute myocardial infarction, transmural healed myocardial infarction and unstable angina pectoris. Am J Cardiol 1989; 64:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/27\">",
"      Roberts WC, Virmani R. Quantification of coronary arterial narrowing in clinically-isolated unstable angina pectoris. An analysis of 22 necropsy patients. Am J Med 1979; 67:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/28\">",
"      Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47:C13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/29\">",
"      Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/30\">",
"      Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation 1982; 66:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/31\">",
"      Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/32\">",
"      Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/33\">",
"      Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Circulation 1995; 92:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/34\">",
"      Chen L, Chester MR, Redwood S, et al. Angiographic stenosis progression and coronary events in patients with 'stabilized' unstable angina. Circulation 1995; 91:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/35\">",
"      Chester MR, Chen L, Kaski JC. The natural history of unheralded complex coronary plaques. J Am Coll Cardiol 1996; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/36\">",
"      Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/37\">",
"      Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001; 37:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/38\">",
"      Hong MK, Mintz GS, Lee CW, et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 2004; 110:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/39\">",
"      Burke A, Virmani R. Significance of multiple coronary artery thrombi. A consequence of diffuse atherosclerotic disease? Ital Heart J 2000; 1:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/40\">",
"      Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation 2003; 108:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/41\">",
"      Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/42\">",
"      Kusama I, Hibi K, Kosuge M, et al. Impact of plaque rupture on infarct size in ST-segment elevation anterior acute myocardial infarction. J Am Coll Cardiol 2007; 50:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/43\">",
"      Tanaka A, Imanishi T, Kitabata H, et al. Morphology of exertion-triggered plaque rupture in patients with acute coronary syndrome: an optical coherence tomography study. Circulation 2008; 118:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/44\">",
"      Toutouzas K, Tsiamis E, Karanasos A, et al. Morphological characteristics of culprit atheromatic plaque are associated with coronary flow after thrombolytic therapy: new implications of optical coherence tomography from a multicenter study. JACC Cardiovasc Interv 2010; 3:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/45\">",
"      Burke AP, Kolodgie FD, Farb A, et al. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/46\">",
"      Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/47\">",
"      Achenbach S, Ulzheimer S, Baum U, et al. Noninvasive coronary angiography by retrospectively ECG-gated multislice spiral CT. Circulation 2000; 102:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/48\">",
"      Hoffmann MH, Shi H, Schmitz BL, et al. Noninvasive coronary angiography with multislice computed tomography. JAMA 2005; 293:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/49\">",
"      Schroeder S, Kopp AF, Baumbach A, et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 2001; 37:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/50\">",
"      Leber AW, Knez A, Becker A, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J Am Coll Cardiol 2004; 43:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/51\">",
"      Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 2006; 47:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/52\">",
"      Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009; 54:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/53\">",
"      Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/54\">",
"      Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol 2010; 55:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/55\">",
"      Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/56\">",
"      Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/57\">",
"      Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/58\">",
"      Epps KC, Wilensky RL. Lp-PLA- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011; 269:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/59\">",
"      Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010; 122:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/60\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/61\">",
"      Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/62\">",
"      Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/63\">",
"      Bustos C, Hern&aacute;ndez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/64\">",
"      Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005; 111:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/65\">",
"      Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol 2003; 42:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/66\">",
"      Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/67\">",
"      Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/68\">",
"      Otsuka F, Hibi K, Kusama I, et al. Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Atherosclerosis 2010; 213:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25721/abstract/69\">",
"      Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 2009; 202:491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1480 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25721=[""].join("\n");
var outline_f25_7_25721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13452933\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452767\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452783\">",
"      PLAQUE FEATURES RESPONSIBLE FOR ACUTE THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452790\">",
"      Plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76054075\">",
"      Plaque erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452804\">",
"      Calcified nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452847\">",
"      PLAQUE MORPHOLOGY IN ACUTE CORONARY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452854\">",
"      Sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452861\">",
"      Acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452869\">",
"      Unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452876\">",
"      Age and sex differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174918233\">",
"      Other correlates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174918240\">",
"      Repeat plaque ruptures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452883\">",
"      OBSERVATIONS IN PATIENTS WITH PLAQUE RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452891\">",
"      VULNERABLE PLAQUES AND FUTURE RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452905\">",
"      Identification of vulnerable plaque by CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13452912\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174916746\">",
"      RISK FACTORS AND FATAL PLAQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452919\">",
"      STATIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13452933\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1480|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44311\" title=\"figure 1\">",
"      Plaque features responsible for acute thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/44/15050\" title=\"figure 2\">",
"      Progression of human coronary atherosclerosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/15/23799\" title=\"figure 3\">",
"      Progression of human coronary atherosclerosis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1480|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/40/37514\" title=\"picture 1\">",
"      Gross and light microscopic features of plaque rupture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_7_25722="Colorectal cancer surveillance in inflammatory bowel disease";
var content_f25_7_25722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colorectal cancer surveillance in inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Robert D Odze, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/7/25722/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/7/25722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inflammatory bowel disease (IBD) are at increased risk for colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. The risk is related to the duration and anatomic extent of the disease. The mortality in patients diagnosed with colorectal cancer in the setting of IBD is higher than for sporadic colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no large controlled trials have proven that surveillance reduces mortality, surveillance is recommended by the American Gastroenterological Association (AGA) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], the American College of Gastroenterology (ACG) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/12\">",
"     12",
"    </a>",
"    ], the American Society for Gastrointestinal Endoscopy (ASGE) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/13\">",
"     13",
"    </a>",
"    ], and the British Society of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and pathology of colon cancer in IBD and the evidence supporting a role for cancer surveillance will be reviewed here. Newer techniques for cancer surveillance will also be discussed, although there is insufficient evidence to support their widespread use. The definition, risk factors, clinical manifestations, diagnosis, and management of IBD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of colorectal cancer (CRC) is increased in ulcerative colitis (UC) and Crohn's disease (CD). However, much more is known about the risk in UC. A population-based study from Sweden estimated that the overall risk of colorectal cancer in inflammatory bowel disease (IBD) was 95 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/16\">",
"     16",
"    </a>",
"    ]. The risk of colorectal cancer in patients with UC appears to have decreased over time but it is unclear if this is due to improved medical therapy and dysplasia surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also unclear if there is a gender difference in the risk for colorectal cancer. In a population-based study of more than 7000 patients with IBD, males had a 60 percent higher risk of CRC than females (cumulative incidence 40 years after diagnosis, 8 versus 3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/18\">",
"     18",
"    </a>",
"    ]. The effect of sex was seen only after ten years of follow-up and limited to patients diagnosed before age 45. This gender difference may be explained by differences in the extent of inflammation, or by factors related to patient behaviors leading to differences in medication or surveillance exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of CRC in UC depends upon the duration and extent of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/1-3,17,20-22\">",
"     1-3,17,20-22",
"    </a>",
"    ]. A population-based study in the United States estimated the risk was significantly increased in those with extensive or pancolitis (standardized incidence ratio (SIR) 2.4, 95% CI 0.6-6.0). In addition, patients with UC complicating primary sclerosing cholangitis (PSC) may be at increased risk for CRC compared to those without PSC. A case control study (in which cases and controls were matched for the extent and duration of disease) found that the risk of CRC was reduced with use of anti-inflammatory agents (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal anti-inflammatory drugs, and 5-aminosalicylic acid agents) and by surveillance colonoscopy while it was increased in patients with a history of postinflammatory pseudopolyps [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pancolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disease extending to the hepatic flexure or more proximally have the greatest risk of CRC. Compared to an age-matched population, the risk begins to increase eight to 10 years following the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The approximate cumulative incidence of CRC is 5 to 10 percent after 20 years and 12 to 20 percent after 30 years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/4,24,27-29\">",
"     4,24,27-29",
"    </a>",
"    ]. Lower rates of CRC have also been found [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a population-based study from Copenhagen, the risk of CRC was not different from the general population, a finding that the authors hypothesize may have been due to an active surgical approach in medical treatment failures and long-term use of 5-ASA drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/31\">",
"     31",
"    </a>",
"    ]. The highest cancer risks have been reported by medical centers that predominantly receive referral patients who may have more severe or longstanding disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, the absolute risk of CRC in patients with pancolitis was 30 percent after 35 years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk was increased in those with the onset of symptoms prior to age 15. However, in other reports, the age of onset of colitis did not increase the risk of CRC after adjusting for the longer period of time that young patients were at risk and the extent of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study suggested that the presence of \"backwash ileitis\" (in which mucosal inflammation involves the terminal ileum) may be an independent risk factor for CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/32\">",
"     32",
"    </a>",
"    ]. However, other studies have not confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Backwash ileitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of inflammation may also be an important marker of risk. A case-control study found a significant correlation between the severity of inflammation as assessed by histology and the risk of colorectal neoplasia (OR 4.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/33\">",
"     33",
"    </a>",
"    ]. A similar degree of risk was found in a later cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Left-sided colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that the risk of CRC increases after 15 to 20 years (approximately one decade later than in pancolitis) in patients with colitis confined to the left colon (ie, distal to the splenic flexure) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/36\">",
"     36",
"    </a>",
"    ]. However, rates of CRC and dysplasia similar to those seen in patients with pancolitis have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative proctitis and proctosigmoiditis are probably not at increased risk for CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of CRC has been observed in patients with UC complicated by PSC. Cancer in patients with PSC was more likely to be in the right colon, suggesting a possible role of bile acids in oncogenesis (a hypothesis supported by studies showing a protective effect of ursodeoxycholic acid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of CRC in longstanding Crohn's disease (CD) involving the colon is probably comparable to ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/5-8,39-42\">",
"     5-8,39-42",
"    </a>",
"    ]. However, not all studies reached these conclusions and thus the magnitude of risk in patients with CD remains unsettled. Some reports found no increased risk of CRC in patients with CD, but most did not adjust for the duration and extent of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. The following studies support the need for CRC surveillance in patients with CD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study from Sweden, the relative risk of colon cancer was 2.5 in patients with CD and 5.6 in those with disease restricted to the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/8\">",
"       8",
"      </a>",
"      ]. The relative risk was even greater in patients who were less than 30 at the time of diagnosis (relative risk 21 compared to those diagnosed after age 30). Similar findings have been reported in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/5,47,48\">",
"       5,47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report suggested the benefit from regular surveillance in patients with Crohn's colitis of at least seven years duration (and affecting at least one-third of the colon) was similar to that of ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a population-based study from the United States (which did consider disease duration) found a significantly increased risk of small bowel but not colorectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CRC in CD is observed in a similar time frame as in UC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This was illustrated in one series that included 80 patients with CRC complicating UC or CD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/49\">",
"     49",
"    </a>",
"    ]. The median duration of disease prior to the diagnosis of CRC was comparable for CD and UC (15 and 18 years, respectively). The median age at diagnosis of CRC was 55 in CD and 43 in UC. One series found that CD patients undergoing surgery for cancer had more advanced CRC than patients with UC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the increased risk, the absolute number of patients at risk is relatively small. Many patients with extensive colitis undergo colectomy early in the course of disease to relieve persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/50\">",
"     50",
"    </a>",
"    ]. Furthermore, sporadic CRC is far more common than CRC arising in the setting of IBD. As a result, CD accounts for a small proportion of CRC for the overall population (",
"    <a class=\"graphic graphic_figure graphicRef70529 \" href=\"UTD.htm?33/7/33917\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of colon cancer in inflammatory bowel disease (IBD) is poorly understood. However, several lines of evidence suggest that the pathobiology is different than for sporadic colorectal cancer (CRC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age of developing CRC in the setting of IBD is lower than for sporadic CRC (40 to 50 versus 60 years).",
"     </li>",
"     <li>",
"      Dysplasia in ulcerative colitis (UC) is preceded by a long history of chronic inflammation and can be found at distant sites from the cancer. In contrast, dysplasia in sporadic colon cancer is usually associated with a discrete polyp without inflammation.",
"     </li>",
"     <li>",
"      Mutations in the ras protooncogene are present in 40 to 60 percent of sporadic colon cancers and are probably an early event; in contrast, these mutations are less frequently observed in cancer associated with UC, and are probably a late event [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of heterozygosity for the p53 gene and src activation occur earlier in cancers associated with IBD than in sporadic CRC [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/52,54-56\">",
"       52,54-56",
"      </a>",
"      ]. Src activity in UC correlates with the degree of dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities of the p53 locus are absent in nondysplastic mucosa of patients with sporadic colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/57\">",
"       57",
"      </a>",
"      ]. In contrast, nondysplastic mucosa in UC frequently has aneuploid DNA content and may show clones of cells with loss of heterozygosity of the p53 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) complicating inflammatory bowel disease may appear polypoid, nodular, ulcerated, or plaque-like [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/58\">",
"     58",
"    </a>",
"    ]. As in sporadic colorectal cancer, most lesions in the colon are adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/59\">",
"     59",
"    </a>",
"    ]. However, poorly differentiated, anaplastic, and mucinous carcinomas are more common in colitis-associated CRC than in sporadic CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/7,54,60,61\">",
"     7,54,60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link\">",
"     \"Pathology and prognostic determinants of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRC associated with ulcerative colitis (UC) is most common in the rectum and sigmoid colon (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63411 \" href=\"UTD.htm?9/60/10191\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, CRC associated with CD is evenly distributed between the right colon and rectosigmoid. Cancer always occurs in areas involved in chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/49\">",
"     49",
"    </a>",
"    ]. Synchronous tumors are much more common in inflammatory bowel disease (IBD) than in sporadic CRC (12 versus 3 to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/54\">",
"     54",
"    </a>",
"    ]. This can include the colon, rectum, anus, and internal or external fistulous tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally accepted that CRC in IBD is preceded by dysplasia. Thus, dysplastic epithelium may be a marker for coexisting malignancy, and provides the rationale for surveillance.",
"   </p>",
"   <p>",
"    A uniform terminology for dysplasia in IBD has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/62\">",
"     62",
"    </a>",
"    ]. The classification categorizes histology as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Negative",
"     </li>",
"     <li>",
"      Indefinite",
"     </li>",
"     <li>",
"      Positive (with subgroups of low grade and high grade dysplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysplastic areas are often difficult to recognize on endoscopy. They may appear as flat or only slightly elevated above the level of the mucosa. Dysplasia may also occur within or near raised plaque-like lesions, nodules, polyps, or masses (referred to as dysplasia-associated lesion or mass [DALM]) (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Dysplasia associated lesion or mass'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Dysplasia may be difficult to distinguish from epithelial regeneration due to inflammation on histologic sections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/63\">",
"     63",
"    </a>",
"    ]. As a result, the presence of dysplasia should be confirmed by an experienced GI pathologist. The criteria for dysplasia stress the uniform clonal nature of dysplastic changes, which affects all parts of the crypt and surface epithelium. In contrast, regenerative changes are usually most prominent at the bases of the crypts and show evidence of surface maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/62\">",
"     62",
"    </a>",
"    ]. One study found that immunostaining for alpha-methylacyl-Coa-racemase (AMACR), a mitochondrial and peroxisomal enzyme overexpressed in many types of cancers, was highly specific for detecting dysplasia and distinguishing regenerating epithelium from true dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other architectural and cytological abnormalities seen in dysplastic epithelium include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/62,65-67\">",
"     62,65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased mitoses (typical and atypical)",
"     </li>",
"     <li>",
"      Back to back gland pattern",
"     </li>",
"     <li>",
"      Increased nuclear size",
"     </li>",
"     <li>",
"      Variation in the size and shape of nuclei (pleomorphism)",
"     </li>",
"     <li>",
"      Increased",
"      <span class=\"nowrap\">",
"       nuclear/cytoplasmic",
"      </span>",
"      ratio",
"     </li>",
"     <li>",
"      Altered nuclear polarity",
"     </li>",
"     <li>",
"      Hyperchromaticity",
"     </li>",
"     <li>",
"      Lack of surface maturation",
"     </li>",
"     <li>",
"      Stratification of nuclei",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dysplasia associated lesion or mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ulcerative colitis have the same risk for sporadic adenomas as the general population. However, some patients with UC who are found to have dysplasia associated with a non-adenoma-like lesion or mass (DALM) may have an underlying invasive carcinoma, which may not be detectable by endoscopic biopsy and warrants colectomy. The risk of cancer associated with DALM was illustrated in a series that included 12 patients with DALM who underwent resection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/68\">",
"     68",
"    </a>",
"    ]. The endoscopic appearance of the lesions was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Single polypoid mass (five patients)",
"     </li>",
"     <li>",
"      Plaque-like lesion (two patients)",
"     </li>",
"     <li>",
"      Multiple polyps (five patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Invasive carcinoma was found on resection specimens in seven patients (60 percent), including all five who had a single polypoid mass. Malignancy was not detected in any of the patients prior to resection despite multiple biopsies.",
"   </p>",
"   <p>",
"    Whereas non-adenoma-like DALMs is an indication for colectomy, sporadic adenomas may be removed endoscopically even if they occur in an area histologically involved with colitis. As a result, non-adenoma-like DALMs and sporadic adenomas need to be distinguished to prevent unnecessary colectomy.",
"   </p>",
"   <p>",
"    A number of clinical, histologic, and molecular features have been studied to help make this distinction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with non-adenoma-like DALM are more likely to be younger and have a longer duration of disease, more extensive disease, and larger lesions (1.8 versus 0.5 cm in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/69\">",
"       69",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Lesions that appear endoscopically as adenomas (pedunculated or sessile) rather than having other characteristics (such as flat, ulcerated, or plaque-like appearance) even if within an area of histologic colitis have a favorable prognosis with endoscopic removal and close follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/70-73\">",
"       70-73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta catenin and P53 are molecular markers that have been proposed to distinguish DALM from sporadic adenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. Beta catenin is a cell membrane protein that accumulates more frequently in nuclei of cells within sporadic colon cancer compared to DALM. In comparison, mutations with P53 (a tumor suppressor gene) occur more frequently in DALM than sporadic adenomas. In one study, for example, these markers were compared in 17 adenoma-like DALM specimens and 21 sporadic adenomas in patients with UC [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/76\">",
"       76",
"      </a>",
"      ]. Positive staining for P53 was more common in DALM (29 versus 5 percent), whereas positive staining for beta catenin was more common in sporadic adenomas (40 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term follow-up suggests that polypectomy with complete excision and continued surveillance provides adequate treatment of patients with an adenoma-like DALM. One study evaluated outcomes of 34 patients with ulcerative colitis of whom 24 had an adenoma-like DALM and 10 had a coincidental sporadic adenoma, 28 of whom were treated by polypectomy and continued surveillance and six by colonic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/71,77\">",
"     71,77",
"    </a>",
"    ]. Outcomes were compared with 49 non-UC patients who were treated similarly for sporadic adenomas. Mean follow-up ranged from 72 to 82 months. Overall, 59 percent of the UC patients developed at least one further adenoma-like DALM. However, there were no significant differences in the incidence of polyp formation on follow-up between UC patients with an adenoma-like DALM and UC patients with a sporadic adenoma or non-UC sporadic adenoma patients.",
"   </p>",
"   <p>",
"    It is important to acknowledge that the study was small (and therefore potentially underpowered to detect differences) and that these patients had been carefully selected based upon their endoscopic findings. Whether a similar degree of certainty in distinguishing adenoma-like DALMs from non-adenoma-like DALMs can be generalized to other clinical settings remains to be tested in a prospective fashion. Our approach to patients with ulcerative colitis who are found to have a polyp is discussed below (see",
"    <a class=\"local\" href=\"#H37\">",
"     'Summary and recommendations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inflammatory pseudopolyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory pseudopolyps are irregularly shaped islands of residual intact colonic mucosa that are the result of the mucosal ulceration and regeneration that occurs in inflammatory bowel disease (IBD). These polyps are typically multiple and scattered throughout the colitic region of the colon (",
"    <a class=\"graphic graphic_picture graphicRef76729 \" href=\"UTD.htm?34/33/35358\">",
"     picture 1",
"    </a>",
"    ). They are not dysplastic and are not a risk factor for colon cancer. However, their presence can complicate the recognition of true adenomas and DALM. Inflammatory pseudopolyps can be recognized by their histologic features; thus a biopsy can help make the distinction in unclear cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREDICTIVE VALUE OF DYSPLASIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of dysplasia has been best studied in ulcerative colitis (UC). There is general agreement that the finding of high-grade dysplasia warrants prompt colectomy because of the high rate of synchronous colorectal cancer (eg, 42 percent [10 of 24] in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More controversial is the proper course of action in patients found to have low-grade dysplasia who are at lower risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/78-85\">",
"     78-85",
"    </a>",
"    ]. The following highly variable rates of progression to high-grade dysplasia or colorectal cancer (CRC) were noted in patients with low-grade dysplasia in different studies with different durations of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      19 percent (3 of 16) had CRC at immediate colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      34 percent (26 of 77) had CRC at colectomy at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      50 percent (9 of 18) progressed to a more advanced lesion (eg, high-grade dysplasia or CRC) at a median of 32 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      15 percent (7 of 46) progressed to CRC at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      10 percent (3 of 29) progressed to high-grade dysplasia or CRC at 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although dysplasia is a marker for future or concurrent malignancy, it can also regress or remain stable for long periods [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/65,86\">",
"     65,86",
"    </a>",
"    ]. There is currently no reliable way to predict which of these outcomes is most likely. Furthermore, most patients with dysplasia do not have cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/29,87,88\">",
"     29,87,88",
"    </a>",
"    ], and dysplasia is absent in the colonic regions distant from the malignancy in 25 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/83,89,90\">",
"     83,89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further complicate matters, the diagnosis of dysplasia is not straightforward, even when using specific criteria for diagnosis. Interpretation of biopsy samples may be confounded by interobserver variation in the recognition and grading of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/83,91,92\">",
"     83,91,92",
"    </a>",
"    ]. As a result, it is important that difficult cases be reviewed by a pathologist who is experienced in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between dysplasia and CRC in CD appears to be similar to that in UC. Dysplasia is present in 83 to 100 percent of patients diagnosed with CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/7,60,61\">",
"     7,60,61",
"    </a>",
"    ], and dysplasia distant from the cancer has been found in 23 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/60,61,93,94\">",
"     60,61,93,94",
"    </a>",
"    ]. In contrast, dysplasia is much less common in colectomy specimens of patients with CD without CRC, occurring in only 2 percent of specimens in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively young age at which colorectal cancer (CRC) develops in patients with inflammatory bowel disease (IBD) has led to attempts to stratify patients at greatest risk. The goal of most surveillance programs has been the detection of dysplasia, which is associated with a high risk of CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/37,49,96,97\">",
"     37,49,96,97",
"    </a>",
"    ]. There are conflicting data as to whether patients with CRC associated with IBD have a worse or similar prognosis compared to patients with sporadic CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/98-102\">",
"     98-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal surveillance strategy in patients with IBD remains controversial. The debate revolves around the sensitivity of the detection system, the predictive value of dysplasia for assessing the risk of CRC, and the cost [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/25,26,78,79,86,103,104\">",
"     25,26,78,79,86,103,104",
"    </a>",
"    ]. Detection of dysplasia is important because concurrent CRC is common. In a review of 10 prospective studies with a total of 1225 patients, high- or low-grade dysplasia was associated with CRC at immediate colectomy in 13 of 40 patients (33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Predictive value of dysplasia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is also unclear if surveillance improves patient survival. Outcomes after the diagnosis of CRC were evaluated in a study of 149 patients with IBD-associated CRC: 23 had undergone colonoscopic surveillance prior to the discovery of CRC, while 126 patients had not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/105\">",
"     105",
"    </a>",
"    ]. Five-year survival was significantly higher in the prior surveillance group (100 versus 74 percent). In contrast, in a pooled analysis of three observational studies (published before the above report), death from CRC was nonsignificantly lower with surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/106\">",
"     106",
"    </a>",
"    ]. The somewhat conflicting findings may be explained by the low rate at which dysplasia was detected.",
"   </p>",
"   <p>",
"    Other issues are that advanced CRC can occur despite surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/21,86,107\">",
"     21,86,107",
"    </a>",
"    ] and the effectiveness of surveillance programs has been limited by both patient compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] and unwillingness to undergo prophylactic colectomy when dysplasia is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the data supporting the effectiveness of surveillance in patients with IBD are not uniform but suggest a reduction in mortality from CRC in patients undergoing surveillance who are willing to undergo prophylactic colectomy. As a result, the current balance of evidence provides some support for routine colonoscopic surveillance for dysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108526913\">",
"    <span class=\"h2\">",
"     Surveillance in patients with dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with unifocal, flat, low-grade dysplasia on initial surveillance colonoscopy, a decision-analysis estimated the cost-effectiveness of enhanced surveillance (colonoscopy at three, six, and 12 months, then annually) versus immediate colectomy in a simulated cohort of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/109\">",
"     109",
"    </a>",
"    ]. Immediate colectomy was associated with higher quality-adjusted life years and lower costs. Enhanced surveillance was cost-effective only when considering health utilities of living with a proctocolectomy that were generally lower than what was considered to be likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108526943\">",
"    <span class=\"h2\">",
"     Surveillance techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Colonoscopy with biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple biopsies are required to adequately sample the colon. In one report, it was estimated that 33 biopsy specimens from a single colonoscopy would be required to detect dysplasia with 90 percent confidence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/110\">",
"     110",
"    </a>",
"    ]. In addition, areas of mucosal irregularity should be biopsied [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/111\">",
"     111",
"    </a>",
"    ]. Guidelines for biopsies have been proposed in the society guidelines summarized below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Recommendations of major societies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A study comparing eight paired biopsy specimens from the rectosigmoid obtained by either jumbo or standard large-capacity forceps concluded that the jumbo forceps were superior for obtaining diagnostically adequate surveillance biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/112\">",
"     112",
"    </a>",
"    ]. Thus, use of jumbo forceps has the potential to improve the dysplasia detection rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chromoendoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromoendoscopy involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A least one controlled trial suggested that staining with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    enhanced the ability to detect the extent of inflammatory changes and identify intraepithelial neoplasia in patients with ulcerative colitis undergoing surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/113\">",
"     113",
"    </a>",
"    ]. Other studies have suggested that staining with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    permitted better detection of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. The clinical implications and generalizability of these findings require further clarification. Other staining techniques designed to augment visualization of dysplastic changes have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     New markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limitations of surveillance strategies based upon the detection of dysplasia, newer techniques involving the detection of alterations in mucosal antigens and genetic abnormalities are being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/57,116\">",
"     57,116",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sialosyl-Tn is a mucin-associated carbohydrate antigen that may presage the development of dysplasia and CRC by several years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/54,117\">",
"       54,117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allelic deletions and point mutations of tumor suppressor genes, such as p53, Rb, mcc and APC have been found in dysplastic and cancerous ulcerative colitis (UC) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/54,57,118\">",
"       54,57,118",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that changes in nuclear DNA content are detectable earlier than histologic signs of premalignancy. As a result, detection of DNA aneuploidy by flow cytometry of mucosal specimens in UC patients may be more objective and less sensitive to assessment error than dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/116\">",
"     116",
"    </a>",
"    ]. DNA aneuploidy detected by these techniques has been correlated with dysplasia and carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/91,119,120\">",
"     91,119,120",
"    </a>",
"    ]. However, as with dysplasia, the predictive value of aneuploidy is uncertain. Neoplasms can arise without preexisting aneuploidy, and conversely, aneuploidy may exist for many years without progression to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These newer techniques have been insufficiently standardized and validated in the clinical setting to be recommended for general use. Until further data are available, endoscopic evaluation for dysplasia remains the standard for cancer surveillance programs in IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF MAJOR SOCIETIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal surveillance strategies for CRC in patients with inflammatory bowel disease (IBD) have not been established. The following recommendations have been issued by the major national societies in the United States and the British Society of Gastroenterology. Our approach to surveillance is summarized below. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ulcerative colitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     American Gastroenterological Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued by the American Gastroenterological Association (AGA) recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonoscopic surveillance should begin after eight years in patients with pancolitis, and 15 years in patients with colitis involving the left colon",
"     </li>",
"     <li>",
"      Colonoscopy should be repeated every one to two years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     American College of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued by the American College of Gastroenterology (ACG) recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annual surveillance colonoscopy beginning after 8 to 10 years of disease in patients who are surgical candidates",
"     </li>",
"     <li>",
"      Multiple biopsies should be obtained at regular intervals",
"     </li>",
"     <li>",
"      The finding of definite dysplasia (of any grade) should be confirmed by an expert pathologist and is an indication for colectomy",
"     </li>",
"     <li>",
"      Patients whose biopsies are indefinite for dysplasia after review by an expert pathologist should undergo repeat surveillance colonoscopy at a shorter interval",
"     </li>",
"     <li>",
"      The ACG recommendations do not specify whether surveillance can begin later in patients with disease limited to the left colon",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     American Society for Gastrointestinal Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Gastrointestinal Endoscopy (ASGE) guidelines recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ulcerative colitis who have pancolitis should begin surveillance colonoscopy after eight years of disease.",
"     </li>",
"     <li>",
"      Four biopsies should be obtained every 10 cm from the cecum to the rectum. In addition, any suspicious lesions or masses should be biopsied.",
"     </li>",
"     <li>",
"      Colonoscopy should be repeated every one to three years.",
"     </li>",
"     <li>",
"      The finding of carcinoma or high-grade dysplasia is an indication for colectomy. Colectomy is also indicated for any degree of dysplasia associated with a lesion or mass. The finding of dysplasia should be confirmed by an expert pathologist.",
"     </li>",
"     <li>",
"      The finding of low-grade dysplasia should be confirmed by an expert pathologist. The ASGE acknowledges that most experts recommend colectomy. However, in patients in whom colectomy is not feasible or is unacceptable, frequent surveillance (eg, every three to six months) is considered an acceptable alternative.",
"     </li>",
"     <li>",
"      Patients with left-sided colitis surveillance should begin surveillance after 15 years of disease. Surveillance is not indicated in ulcerative proctitis. The ASGE also recommends that prophylactic colectomy should be considered in patients with longstanding colitis. The definition of longstanding was not specified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     British Society of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued by the British Society of Gastroenterology in 2002 and updated in 2010 recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance colonoscopies should be performed when the disease is in remission, if possible. However, a surveillance procedure should not be unduly delayed if remission cannot be achieved.",
"     </li>",
"     <li>",
"      All patients should have a surveillance colonoscopy 10 years after the onset of symptoms to assess disease extent and other endoscopic risk factors.",
"     </li>",
"     <li>",
"      The interval for surveillance colonoscopy depends upon the duration and extent of disease and the presence of additional risk factors (eg, family history of colon cancer or primary sclerosing cholangitis).",
"      <br/>",
"      <br/>",
"      Surveillance should be performed every five years for patients at lower risk (extensive colitis with no active endoscopic or histologic inflammation, left-sided colitis, or Crohn&rsquo;s colitis involving less than 50 percent of the colon).",
"      <br/>",
"      <br/>",
"      Surveillance should be performed every three years for patients at intermediate risk (extensive colitis with mildly active endoscopic or histologic inflammation, post-inflammatory polyps, or a family history of colorectal cancer in a first-degree relative who was at least 50 years of age).",
"      <br/>",
"      <br/>",
"      Surveillance should be performed every year for patients at higher risk (extensive colitis with moderately active endoscopic or histologic inflammation, a stricture in the preceding five years, dysplasia in the previous five years that was not treated surgically, primary sclerosing cholangitis, or a family history of colorectal cancer in a first-degree relative younger than 50 years of age).",
"     </li>",
"     <li>",
"      Pancolonic dye spraying with targeted biopsies of abnormal areas. If chromoendoscopy is not used, two to four random biopsy specimens every 10 cm from the entire colon should be taken with additional samples of suspicious areas.",
"     </li>",
"     <li>",
"      If a dysplastic polyp is detected within an area of inflammation and can be removed in its entirety, it is not necessary to recommend colectomy.",
"     </li>",
"     <li>",
"      Postcolectomy surveillance with yearly flexible sigmoidoscopy of",
"      <span class=\"nowrap\">",
"       pouch/rectal",
"      </span>",
"      mucosa should be considered for patients at high risk (previous rectal dysplasia or dysplasia or colorectal cancer at the time of pouch surgery or primary sclerosing cholangitis or type C mucosa [mucosa exhibiting permanent persistent atrophy and severe inflammation] in the pouch). In patients with none of the risk factors above, five-yearly flexible sigmoidoscopy of",
"      <span class=\"nowrap\">",
"       pouch/rectal",
"      </span>",
"      mucosa should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Crohn's disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     American Gastroenterological Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AGA concluded that the risk of colorectal cancer associated with ulcerative colitis (UC) and Crohn's colitis is similar for comparable extent, duration, and age of onset of inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. As a result, the surveillance strategy discussed above for UC also applies for Crohn's colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     American College of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACG recognizes the expanding evidence of the carcinogenic potential of longstanding Crohn's disease but found insufficient evidence to provide guidelines for surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     American Society for Gastrointestinal Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASGE also recognizes that the risk of colorectal cancer is increased in Crohn's colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/13\">",
"     13",
"    </a>",
"    ]. Surveillance colonoscopy and biopsy for dysplasia should be offered to patients with longstanding Crohn's colitis. However, the ASGE finds that the data guiding the selection of intervals and proper performance of biopsies are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     British Society of Gastroenterology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for ulcerative colitis also apply to Crohn's colitis in a guideline issued by the British Society of Gastroenterology (see",
"    <a class=\"local\" href=\"#H30\">",
"     'British Society of Gastroenterology'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108526719\">",
"    <span class=\"h1\">",
"     CHEMOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is presently no drug that is generally considered to be effective in the primary prevention of colorectal cancer in patients with inflammatory bowel disease (IBD). Thus, chemoprophylaxis is not recommended. Several drugs have been studied in the non-IBD population (particularly nonsteroidal antiinflammatory drugs and calcium) and some have also been evaluated in IBD and in the aggregate have not been found to be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .) The latter include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , fatty acids, and ursodeoxycholic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/122-126\">",
"     122-126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several lines of evidence also suggest that the risk may be reduced with aminosalicylates, but studies have been mixed and magnitude of benefit is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .) In contrast, 6-mercaptopurine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    does not appear to influence the rate of neoplastic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consensus that patients with ulcerative colitis (UC) should undergo surveillance colonoscopy, although the interval in which this should be done and the optimal number and location that biopsies should be obtained are uncertain. Furthermore, a reduction in mortality due to surveillance has not been clearly established. Patients with Crohn's colitis probably have the same risk of colorectal cancer as those with UC, and should also undergo surveillance. Our current approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with ulcerative colitis extending proximal to the splenic flexure or Crohn's colitis, we suggest initiating surveillance colonoscopy after eight years of disease followed by annual examinations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Those with Crohn's colitis may require use of a thin caliber colonoscope to adequately sample the colon including strictured areas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/7/25722/abstract/40\">",
"       40",
"      </a>",
"      ]. We offer surgical resection to patients with Crohn's colitis who have an impassable stricture since they cannot be surveyed adequately; we suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema in those who decline resection.",
"     </li>",
"     <li>",
"      In patients with left-sided UC, we suggest beginning with colonoscopy after 12 years of disease; examinations are then performed every year thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who have undergone a subtotal colectomy with an ileostomy and have rectum left in place and tied off (ie, a Hartmann's pouch), we suggest surveillance of the remaining rectum every year (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest not performing surveillance for patients with ulcerative colitis limited to the rectum (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with a pouch, we suggest flexible sigmoidoscopy every three to five years in the absence of inflammation and atrophy. However, in the presence of severe inflammation or atrophy we increase the surveillance interval to yearly (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Multiple biopsies are required to adequately sample the colon. We typically obtain four biopsies every 10 cm from the cecum to the rectum. In addition, areas of mucosal irregularity should be biopsied.",
"     </li>",
"     <li>",
"      We recommend colectomy for patients who are found to have high-grade dysplasia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although opinions continue to vary, we also suggest colectomy for those with low-grade dysplasia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In some cases a spontaneous adenoma cannot be distinguished from a non-adenoma-like dysplasia associated lesion or mass (DALM), by either endoscopy or pathology. Lesions can definitely be considered sporadic adenomas if they occur proximal to known areas of colitis (eg, right-sided polyp in a patient with left-sided colitis).",
"     </li>",
"     <li>",
"      For lesions that appear endoscopically and histologically similar to a sporadic adenoma, we suggest performing extensive biopsies in the surrounding area, and in the rest of the colon (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients considered to have a sporadic adenoma who did not have adequate surveillance biopsies obtained throughout the colon at the time of polypectomy should undergo a repeat colonoscopy with surveillance biopsies throughout the colon (and extra attention to the area of the polypectomy); standard surveillance can be resumed if there is no evidence of flat dysplasia.",
"     </li>",
"     <li>",
"      For polyps that appear endoscopically and histologically to be adenomas (ie, adenoma-like DALM) regardless of whether they occurred in an area of the colon involved with colitis and are not associated with dysplastic changes in flat mucosa elsewhere in the colon, we suggest that rather than performing a colectomy, the adenomatous polyp be removed endoscopically with close follow-up (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In the absence of dysplasia in the flat mucosa in the surrounding area or elsewhere in the colon, or invasive carcinoma in the polyp, the clinical aspects of the tumor and the patient's overall clinical status should be considered for recommending further surveillance or colectomy (",
"      <a class=\"graphic graphic_table graphicRef66630 \" href=\"UTD.htm?32/57/33692\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef69534 \" href=\"UTD.htm?5/49/5919\">",
"       algorithm 1",
"      </a>",
"      ). However, most, if not all, adenoma-like lesions can be treated safely by polypectomy and continuous surveillance. Standard surveillance intervals can be continued in patients with low-risk lesions (although shortening the interval between examinations is also reasonable).",
"     </li>",
"     <li>",
"      Non-adenoma-like polyps or other masses occurring in an area of colon that has been histologically involved with colitis, with or without surrounding dysplasia, should be considered as potentially containing invasive carcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/1\">",
"      ROSENQVIST H, OHRLING H, LAGERCRANTZ R, EDLING N. Ulcerative colitis and carcinoma coli. Lancet 1959; 1:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/2\">",
"      Course and prognosis of ulcerative colitis: Part IV Carcinoma of the colon. Gut 1964; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/3\">",
"      MACDOUGALL IP. THE CANCER RISK IN ULCERATIVE COLITIS. Lancet 1964; 2:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/4\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/5\">",
"      Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med 1973; 289:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/6\">",
"      Softley A, Clamp SE, Watkinson G, et al. The natural history of inflammatory bowel disease: has there been a change in the last 20 years? Scand J Gastroenterol Suppl 1988; 144:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/7\">",
"      Richards ME, Rickert RR, Nance FC. Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg 1989; 209:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/8\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/9\">",
"      Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/10\">",
"      Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/11\">",
"      Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/12\">",
"      Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/13\">",
"      Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 63:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/14\">",
"      Eaden JA, Mayberry JF, British Society for Gastroenterology, Association of Coloproctology for Great Britain and Ireland. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51 Suppl 5:V10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/15\">",
"      Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/16\">",
"      S&ouml;derlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/17\">",
"      Jess T, Simonsen J, J&oslash;rgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/18\">",
"      S&ouml;derlund S, Granath F, Brostr&ouml;m O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/19\">",
"      Ullman TA. Inflammatory bowel disease-associated cancers: does gender change incidence? Gastroenterology 2010; 138:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/20\">",
"      Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971; 285:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/21\">",
"      Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/22\">",
"      Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/23\">",
"      Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/24\">",
"      Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/25\">",
"      Lennard-Jones JE. Cancer risk in ulcerative colitis: surveillance or surgery. Br J Surg 1985; 72 Suppl:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/26\">",
"      Collins RH Jr, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med 1987; 316:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/27\">",
"      Katzka I, Brody RS, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis: experience from a private practice. Gastroenterology 1983; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/28\">",
"      Mir-Madjlessi SH, Farmer RG, Easley KA, Beck GJ. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer 1986; 58:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/29\">",
"      Lennard-Jones JE, Melville DM, Morson BC, et al. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 31:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/30\">",
"      Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/31\">",
"      Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/32\">",
"      Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/33\">",
"      Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/34\">",
"      Haskell H, Andrews CW Jr, Reddy SI, et al. Pathologic features and clinical significance of \"backwash\" ileitis in ulcerative colitis. Am J Surg Pathol 2005; 29:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/35\">",
"      Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/36\">",
"      Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/37\">",
"      Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991; 100:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/38\">",
"      Levin B. Inflammatory bowel disease and colon cancer. Cancer 1992; 70:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/39\">",
"      Rubio CA, Befrits R. Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study. Dis Colon Rectum 1997; 40:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/40\">",
"      Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001; 120:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/41\">",
"      Maykel JA, Hagerman G, Mellgren AF, et al. Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis Colon Rectum 2006; 49:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/42\">",
"      Moreels TG, Pelckmans PA. Double-balloon endoscope for failed conventional colonoscopy. Clin Gastroenterol Hepatol 2008; 6:259; author reply 259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/43\">",
"      Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/44\">",
"      Kvist N, Jacobsen O, N&oslash;rgaard P, et al. Malignancy in Crohn's disease. Scand J Gastroenterol 1986; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/45\">",
"      Gollop JH, Phillips SF, Melton LJ 3rd, Zinsmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988; 29:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/46\">",
"      Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn's disease. A population study in central Israel. Scand J Gastroenterol 1989; 24:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/47\">",
"      Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981; 48:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/48\">",
"      Gyde SN, Prior P, Macartney JC, et al. Malignancy in Crohn's disease. Gut 1980; 21:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/49\">",
"      Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/50\">",
"      Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994; 35:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/51\">",
"      Kiran RP, Khoury W, Church JM, et al. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience. Ann Surg 2010; 252:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/52\">",
"      Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/53\">",
"      Burmer GC, Levine DS, Kulander BG, et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990; 99:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/54\">",
"      Itzkowitz SH. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 1997; 26:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/55\">",
"      Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/56\">",
"      Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/57\">",
"      Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/58\">",
"      Butt JH, Konishi F, Morson BC, et al. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. Dig Dis Sci 1983; 28:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/59\">",
"      Connell WR, Sheffield JP, Kamm MA, et al. Lower gastrointestinal malignancy in Crohn's disease. Gut 1994; 35:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/60\">",
"      Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 1985; 89:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/61\">",
"      Petras RE, Mir-Madjlessi SH, Farmer RG. Crohn's disease and intestinal carcinoma. A report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology 1987; 93:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/62\">",
"      Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/63\">",
"      Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/64\">",
"      Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 2006; 30:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/65\">",
"      Albert MB, Nochomovitz LE. Dysplasia and cancer surveillance in inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/66\">",
"      Allen DC, Hamilton PW, Watt PC, Biggart JD. Morphometrical analysis in ulcerative colitis with dysplasia and carcinoma. Histopathology 1987; 11:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/67\">",
"      Allen DC, Hamilton PW, Watt PC, Biggart JD. Architectural morphometry in ulcerative colitis with dysplasia. Histopathology 1988; 12:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/68\">",
"      Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981; 80:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/69\">",
"      Suzuki K, Muto T, Shinozaki M, et al. Differential diagnosis of dysplasia-associated lesion or mass and coincidental adenoma in ulcerative colitis. Dis Colon Rectum 1998; 41:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/70\">",
"      Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol 1999; 94:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/71\">",
"      Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/72\">",
"      Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/73\">",
"      Odze RD, Brown CA, Hartmann CJ, et al. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas. Am J Surg Pathol 2000; 24:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/74\">",
"      Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/75\">",
"      Munemitsu S, Albert I, Souza B, et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995; 92:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/76\">",
"      Walsh SV, Loda M, Torres CM, et al. P53 and beta catenin expression in chronic ulcerative colitis--associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol 1999; 23:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/77\">",
"      Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/78\">",
"      Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/79\">",
"      Ullman TA, Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002; 97:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/80\">",
"      Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/81\">",
"      Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/82\">",
"      Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 2006; 12:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/83\">",
"      Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/84\">",
"      Gorfine SR, Bauer JJ, Harris MT, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum 2000; 43:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/85\">",
"      Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/86\">",
"      Axon AT. Cancer surveillance in ulcerative colitis--a time for reappraisal. Gut 1994; 35:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/87\">",
"      Brostr&ouml;m O, L&ouml;fberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study. Gut 1986; 27:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/88\">",
"      Manning AP, Bulgim OR, Dixon MF, Axon AT. Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease. Gut 1987; 28:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/89\">",
"      Ransohoff DF, Riddell RH, Levin B. Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia. Dis Colon Rectum 1985; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/90\">",
"      Taylor BA, Pemberton JH, Carpenter HA, et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 1992; 35:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/91\">",
"      Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988; 95:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/92\">",
"      Dixon MF, Brown LJ, Gilmour HM, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/93\">",
"      Fresko D, Lazarus SS, Dotan J, Reingold M. Early presentation of carcinoma of the small bowel in Crohn's disease (\"Crohn's carcinoma\"). Case reports and review of the literature. Gastroenterology 1982; 82:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/94\">",
"      Korelitz BI, Lauwers GY, Sommers SC. Rectal mucosal dysplasia in Crohn's disease. Gut 1990; 31:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/95\">",
"      Warren R, Barwick KW. Crohn's colitis with carcinoma and dysplasia. Report of a case and review of 100 small and large bowel resections for Crohn's disease to detect incidence of dysplasia. Am J Surg Pathol 1983; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/96\">",
"      Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer in colitis: assessment of the individual risk by clinical and histological criteria. Gastroenterology 1977; 73:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/97\">",
"      Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995; 108:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/98\">",
"      Jensen AB, Larsen M, Gislum M, et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol 2006; 101:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/99\">",
"      Delaunoit T, Limburg PJ, Goldberg RM, et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/100\">",
"      Aarnio M, Mustonen H, Mecklin JP, J&auml;rvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med 1998; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/101\">",
"      Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg 1993; 218:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/102\">",
"      Ali RA, Dooley C, Comber H, et al. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/103\">",
"      Provenzale D, Wong JB, Onken JE, Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998; 93:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/104\">",
"      Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: more of the same or progress? Gastroenterology 1994; 107:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/105\">",
"      Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009; 101:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/106\">",
"      Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; :CD000279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/107\">",
"      Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol 1990; 85:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/108\">",
"      Choi PM, Nugent FW, Schoetz DJ Jr, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/109\">",
"      Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc 2009; 69:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/110\">",
"      Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/111\">",
"      Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004; 60:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/112\">",
"      Elmunzer BJ, Higgins PD, Kwon YM, et al. Jumbo forceps are superior to standard large-capacity forceps in obtaining diagnostically adequate inflammatory bowel disease surveillance biopsy specimens. Gastrointest Endosc 2008; 68:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/113\">",
"      Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/114\">",
"      Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004; 53:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/115\">",
"      Matsumoto T, Nakamura S, Jo Y, et al. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 2003; 98:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/116\">",
"      L&ouml;fberg R, Brostr&ouml;m O, Karl&eacute;n P, et al. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992; 102:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/117\">",
"      Itzkowitz SH, Young E, Dubois D, et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology 1996; 110:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/118\">",
"      Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992; 52:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/119\">",
"      L&ouml;fberg R, Brostr&ouml;m O, Karl&eacute;n P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology 1990; 99:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/120\">",
"      L&ouml;fberg R, Brostr&ouml;m O, Karl&eacute;n P, et al. Carcinoma and DNA aneuploidy in Crohn's colitis--a histological and flow cytometric study. Gut 1991; 32:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/121\">",
"      Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/122\">",
"      Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/123\">",
"      Hontecillas R, Wannemeulher MJ, Zimmerman DR, et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr 2002; 132:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/124\">",
"      Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993; 119:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/125\">",
"      Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989; 97:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/126\">",
"      Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/7/25722/abstract/127\">",
"      Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005; 3:1015.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4079 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25722=[""].join("\n");
var outline_f25_7_25722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pancolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Left-sided colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Proctitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dysplasia associated lesion or mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inflammatory pseudopolyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREDICTIVE VALUE OF DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108526913\">",
"      Surveillance in patients with dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108526943\">",
"      Surveillance techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Colonoscopy with biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - New markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RECOMMENDATIONS OF MAJOR SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - American Gastroenterological Association",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - American College of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - American Society for Gastrointestinal Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - British Society of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - American Gastroenterological Association",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - American College of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - American Society for Gastrointestinal Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - British Society of Gastroenterology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108526719\">",
"      CHEMOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4079|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/49/5919\" title=\"algorithm 1\">",
"      Rx adenoma like DALM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4079|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/60/10191\" title=\"diagnostic image 1\">",
"      Sigmoid cancer in UC BE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/7/33917\" title=\"figure 1\">",
"      Factors associated with CRC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4079|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35358\" title=\"picture 1\">",
"      Pseudopolyps IBD Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33692\" title=\"table 1\">",
"      DALM versus sporadic adenoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_7_25723="Equipment for arterial line insertion";
var content_f25_7_25723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment for arterial line insertion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravascular catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guidewire appropriate for arterial site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine solution (1 percent) and syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suture material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximal sterile-barrier precautions (drape, gown, mask, gloves,and cap; antiseptic handwash)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Materials to securely immobilize and expose the arterial site (eg, armboard, tape)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid filled noncompliant tubing with stopcocks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transducer and dome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constant flush device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electronic monitoring equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connecting cable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor with amplifier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscilloscope display screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25723=[""].join("\n");
var outline_f25_7_25723=null;
var title_f25_7_25724="Non-ACS causes of elevated troponin";
var content_f25_7_25724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elevations of cardiac troponin in the absence of overt ischaemic heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Damage related to secondary myocardial ischaemia (MI type 2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachy- or bradyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic dissection and severe aortic valve disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo- or hypertension, eg, haemorrhagic shock, hypertensive emergency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute and chronic heart failure without significant concomitant coronary artery disease (CAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary vasculitis, eg, systemic lupus erythematosus, Kawasaki syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary endothelial dysfunction without significant CAD, eg, cocaine abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Damage not related to myocardial ischaemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac contusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac incisions with surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency or cryoablation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyolysis with cardiac involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiotoxic agents, eg, anthracyclines, herceptin, carbon monoxide poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe burns affecting &gt;30 percent of body surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Indeterminant or multifactorial group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apical ballooning syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe pulmonary embolism or pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripartum cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe acute neurological diseases, eg, stroke, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infiltrative diseases, eg, amyloidosis, sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extreme exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute respiratory failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent defibrillator shocks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010; 31:2197, by permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25724=[""].join("\n");
var outline_f25_7_25724=null;
var title_f25_7_25725="Changes in BUN";
var content_f25_7_25725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in blood urea nitrogen measured at different times after dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 223px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in BUN measured at the end of and after hemodialysis. A is the immediate postdialysis sample; B is an immediate postdialysis sample taken from the limb opposite the vascular access to eliminate access recirculation; C is delayed for two minutes to eliminate the effect of cardiopulmonary recirculation; and D is delayed for one hour when urea equilibration should be complete.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Depner, TA, Kidney Int 1994; 45:1522.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25725=[""].join("\n");
var outline_f25_7_25725=null;
var title_f25_7_25726="Malaria eradication phases";
var content_f25_7_25726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Phases of malaria eradication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: World Health Organization. World Malaria Report, 2008. p. 31. Available at file://apps.who.int/malaria/wmr2008/malaria2008.pdf. Copyright &copy; 2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25726=[""].join("\n");
var outline_f25_7_25726=null;
var title_f25_7_25727="Microdeletion FISH";
var content_f25_7_25727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microdeletion FISH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescence in situ hybridization (FISH) of a patient with a deletion of chromosome 22q, the DiGeorge/VCF syndrome. As shown, the VCF probe only hybridizes with one chromosome 22 (red line and arrows). By comparison, the fluorescent green probe is a control probe that hybridizes to both chromosomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_7_25727=[""].join("\n");
var outline_f25_7_25727=null;
